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Abstract
Background: Advancements in the treatment of non-infectious disease have enabled survival
rates to steadily increase in recent decades (e.g., diabetes, heart disease, and cancer).
Epidemiological studies have revealed that the treatments for these diseases can have lifethreatening and/or life–altering effects. Thus, realizing the full beneficial potential of advanced
treatments necessitates new tools to algorithmically consider all major components of the health
outcome, including benefit and detriment. The goal of this dissertation was to develop a
framework for improving projected health outcomes following planned radiation exposures in
consideration of all beneficial and detrimental, early and late, and fatal and non-fatal effects.
Methods: We designed a generally applicable framework for aggregating the benefits and
detriments of planned exposures to individuals, groups, and populations. We demonstrated the
utility of this framework with illustrative hypothetical example applications to emergency
response, diagnostic radiology, and cancer radiotherapy. Finally, we used this new framework to
directly optimize health outcomes in a population of men with prostate cancer receiving
radiotherapy. We compared the resulting projected outcomes to those of conventional treatmentplanning methods.
Results: Applications of the comprehensive framework to three illustrative scenarios revealed the
utility of this framework for guiding objective and algorithmic decision making. Radiotherapy
outcome-optimization methods yielded equivalent or superior projected health outcomes
compared to conventional dose-optimization methods for every patient in the population. On
average, outcome-optimized plans increased the probability of treatment benefit by 1%, while
simultaneously decreasing the cumulative probability of long- and short-term treatment side
effects by 3% compared to conventional treatment plans. We estimate that this would add up to 7
x

additional healthy-life months to each patients’ life expectancy compared to that from
conventional treatment plans.
Conclusions: The major finding is that it is feasible to directly optimize the projected health
outcome of planned radiation exposures (e.g., industrial, diagnostic, or therapeutic) in a
personalized or population-averaged manner. Furthermore, these methods are entirely
compatible with current approaches and limits. This work, taken together, provides a
comprehensive methodological framework that could enable a paradigm shift towards more
objective and automated approaches to realizing the full beneficial potential of planned
exposures.
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Chapter 1. Introduction
1.1. Background and Motivation
The principles of medical ethics comprise four main tenets: autonomy, beneficence, nonmaleficence, and justice1. When considered together, the tenets of beneficence and nonmaleficence represent what is known as the Hippocratic Oath, which implores medical
practitioners to do no harm. Rarely, however, does there exist a medical intervention free from
all risks of harmful side effects. For example, while advancements in non-infectious disease
treatments have enabled survival rates to steadily increase in recent decades (e.g., diabetes2, heart
disease3, and cancer4), studies have revealed that the treatments for these diseases can have lifethreatening and/or life–altering effects5-7. Thus, in practice, medical practitioners aim to ensure
that the benefits of the intervention outweigh the risks of harmful side effects, thereby producing
some net benefit for the patient1. As survival rates continue to rise, however, the number and
complexity of potential benefits and detriments is likely to increase as well, thus necessitating
new tools to algorithmically consider and balance all major components of the health outcome.
Of these non-infectious diseases, cancer is one of the most significant health-care problems in
the world today. It is responsible for 1 in 6 deaths worldwide and is the second leading cause of
death in the developed world8. In the United States, it is estimated that nearly half of all men and
women born today will be diagnosed with some form of cancer in their lifetime9. Furthermore,
increasing cancer-survival rates have created a large and growing population of cancer survivors,
expected to surpass 20 million in the next decade10. The majority of cancer survivors received
radiation therapy as a part of their care, as it is one of the most commonly used tools in the
treatment of cancer11. This is largely due to the many benefits of radiation therapy, which include
that the treatment is considered safe, effective, and is one of the least invasive of the cancer1

treatment options. As with most medical interventions, however, radiotherapy is not free from
risks of side effects.
The side effects with which radiotherapy is linked can be divided into two broad categories:
early and late. Early effects of radiotherapy tend to occur during the course of treatment or
shortly thereafter and include such effects as bladder toxicity12, lung pneumonitis13, and bone
fractures14, to name a few. The late effects of radiotherapy, on the other hand, can occur months,
years, or even decades after the completion of treatment and include effects such as second
cancer15, cardiac toxicity16, and fertility complications17. Epidemiological studies on the large
and growing population of cancer survivors have revealed that many long-term cancer survivors
suffer from one or more of these conditions for the duration of their lifetime7. Thus it would
appear that the full beneficial potential of radiotherapy cannot be realized without innovative
approaches to not only increase rates of tumor cure, but also minimize the myriad long- and
short-term harmful side effects18.
One approach to achieving this is by way of treatment-plan optimization. Most current
radiotherapy treatment-planning methods optimize the spatial distribution of absorbed dose in
the patient. Absorbed dose, however, is a purely physical quantity and is a poor surrogate for the
health outcome19. New developments in treatment-plan optimization instead aim to directly
optimize the clinical goals of treatment, namely, the patient’s health outcome. Early attempts at
direct optimization replaced purely dosimetric constraints with biologically-guided dosimetric
constraints20, 21. More recent work has focused on replacing dosimetric constraints entirely with
dose-response functions. The majority of these studies only attempted to consider the early
effects of treatment, thereby neglecting the patient’s long-term health outcome22-28. Relatively
less is known about optimizing the late effects of radiotherapy29-31. Furthermore, only two of
2

these studies considered the dose deposited by stray-radiation exposures in the healthy tissues
outside of the therapeutic target29, 32, which contributes to the risk of late effects15.
1.2. Statement of the Problem
We lack a framework for combining all outcomes (i.e., beneficial and detrimental, long- and
short-term, fatal and non-fatal) associated with all of the dose (i.e., therapeutic and stray) in all of
the tissues (i.e., diseased and healthy) in individual radiotherapy patients. Doing so necessitates
new methods to combine risks of varying types and severity into a single metric and to directly
optimize the outcomes. It will also require several new tools to calculate and evaluate the dose
from both therapeutic and stray exposures in individual patients. Therefore, the feasibility of
improving projected health outcomes (i.e., inclusive of long- and short-term health effects of
varying severity) by optimizing them directly, rather than their surrogate (i.e., indirectly with
constraints on the distribution of absorbed dose), is currently unknown.
1.3. Objective
The goal of this dissertation was to develop a framework for improving projected health
outcomes following radiation exposures in consideration of all health effects, including
beneficial and detrimental, early and late, and life-threatening and non-life-threatening effects.
We achieved this via practical examples in medicine and occupational radiation protection. For
these examples, we first developed tools to close a chronic gap in the knowledge of radiotherapy
exposures, namely, the evaluation33 (Chapter 2) and calculation34 (Chapter 3) of the absorbed
dose from therapeutic- and stray-radiation exposures in individual patients. Next, we designed a
generally applicable framework for aggregating all of the beneficial and detrimental effects of
planned radiation exposures to individuals, groups, and populations. We demonstrated the utility
of this framework in a variety of planned-radiation-exposure settings with three illustrative
3

example scenarios: emergency response, diagnostic radiology, and cancer radiotherapy35
(Chapter 4). Finally, we used these new dose-calculation and risk-aggregation tools to directly
optimize the health outcomes for a population of prostate-cancer radiotherapy patients. We
compared the projected health outcomes for outcome-optimized treatment plans to those for
conventionally dose-optimized treatment plans to determine the beneficial potential of these new
methods36 (Chapter 5).

4

Chapter 2. An Objective Method to Evaluate Radiation Dose Distributions
Varying by Three Orders of Magnitude
2.1. Introduction
Modern radiotherapy practices require that the absorbed dose to the patient is accurately
predicted to within 5% of the prescribed absorbed dose (Rx ) in order to ensure adequate tumor
control and/or ablation of non-cancer disease (e.g., arteriovenous malformation)37. Additionally,
protecting the surrounding normal tissues from acute injury necessitates the accurate knowledge
of the absorbed dose down to the 5-10% dose level, relative to Rx . Thus, radiotherapy

treatment-plan development38-41 and evaluation42 typically consider dose magnitudes of 5 to 10%

of Rx and higher. Epidemiological studies, however, have revealed a burgeoning population of

long-term cancer survivors4 who are at risk of serious late-occurring health conditions7 including
second cancer15, cardiac toxicity16, and fertility complications17. The low-dose exposures from
radiotherapy (i.e., below the 5 to 10% relative dose level) are implicated in a number of these
side effects15, 17, 43, 44. This has spurred the development of various methods for obtaining these
out-of-field dose magnitudes, including measurements45, analytical model calculations40, 46-50,
and Monte Carlo simulations46, 50-52.
A great deal is known about how to evaluate therapeutic dose distributions (i.e., in regions with

dose () ≥ 5% of Rx ). Typically, the evaluation approach comprises a comparison of reference
and test dose distributions. Metrics like dose difference, distance to agreement, or some
combination of these (e.g., the gamma (γ) index) are well understood and widely used for such
comparisons53-55. Further, for assessing accuracy inside of the therapeutic treatment field, a

This chapter was previously published as L.J. Wilson, W.D. Newhauser, C.W. Schneider, "An
objective method to evaluate radiation dose distributions varying by three orders of magnitude,"
Medical Physics 46, 1888-1895 (2019). Reprinted by permission of John Wiley and Sons.
5

wealth of literature exists on the level of agreement that can be achieved42, 56-58. However, γ index passing rates vary with the user’s selection of agreement criteria, which are selected
subjectively59. Relatively less is known about how to evaluate doses below the 5% relative dose
level. Numerous recent studies reported that γ -index analysis is insensitive to dosimetric
discrepancies outside of the therapeutic dose region60-62. Our review of the literature did not
reveal a method for reliably evaluating the accuracy of dose distributions spanning three orders
of magnitude.
The purpose of this study was to develop a method to assess dosimetric agreement that works
universally, i.e., in both high- and low-dose regions of distributions spanning three orders of
magnitude in dose. To do this, we generalized γ -index analysis methods to include an additional
agreement criterion specifically for the low-dose region (i.e., for doses ≤ 5%). We also created
an algorithm to objectively select the appropriate magnitudes for each agreement criterion. We
then demonstrated this new evaluation method in 1-, 2-, and 3-dimensional dose distributions
obtained from measurements, treatment-planning-system calculations, Monte-Carlo simulations,
and analytical-model calculations.
2.2. Materials and Methods
2.2.1.

Generalized Gamma Index

Traditional γ-index methods utilize a threshold dose, thresh , below which all data are excluded
from analysis. thresh is typically placed between 5 and 10% of Rx , thus limiting the scope of

applicability42. To expand the scope, we generalized traditional γ-index methods. Specifically,

we calculated the generalized gamma index, ΓG , for a 1-dimensional comparison by,

6

ΓG m , c  =


⎧   m , c  "# m , c 

+
, for m where (  > thresh
⎪
 
 
R

⎨    ,   "   ,  
m c
*
m c
⎪
+
, for m where (  ≤ thresh




A
⎩

2.1

where m and c are the locations of measured and calculated dose values, , respectively.

m , c  is the difference in location between measured and calculated dose values. This was
calculated for all combinations m , c  by

m , c  = |m − c |∀0m , c 1.

2.2

"R m , c  is the relative difference between measured and calculated dose values at locations m
and c , computed as

"R m , c  =

c c  − m m 
,
Rx

2.3

where c c  and m m  are the calculated and measured absorbed-dose values at c and m ,
respectively. These two factors are identical to those commonly used in traditional γ-index

analysis. Additionally, the proposed ΓG in Eq. 2.1 includes "A m , c , the absolute dose

difference between measured and calculated dose values at locations m and c , respectively. We

calculated this as
"A m , c  = c c  − m m 

2.4

where c c  and m m  are the same as in Eq. 2.3. Finally,  , R , and A , represent the
ΓG agreement criteria of distance to agreement, relative dose difference, and absolute dose
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difference, respectively. As in traditional γ-index methods, thresh in Eq. 2.1 represents the
threshold dose, which is used here to discriminate between therapeutic and out-of-field locations.
The magnitudes of agreement criteria and the placement of thresh will be discussed in section
2.2.2.
Following traditional γ-index methods, the final generalized-gamma-index array, 2G m , at all

locations m was found by

2G m  = min0ΓG m , c 1∀0c 1.

2.5

Thus, as with traditional γ-index analysis, a value of 2G m  ≤ 1 indicates that the result of a
comparison at m is a pass. A value of 2G m  > 1 signifies a failure at m . For the reader’s
convenience, the corresponding versions of Eqs. 2.1 through 2.5 for 2- and 3-dimensional

comparisons are given in Appendix B. Calculating 2G in this way generalizes γ -index methods
to universally evaluate the high- and low-dose regions, i.e., all data may be included in the
analysis.
2.2.2. Objective Determination of Agreement Criteria

These 2G -index methods include three agreement criteria, two that are used in traditional γ-index

analysis,  and R , and an additional criterion, A . No standard values for this new criterion

yet exist. In addition, it cannot be assumed that  and R values from traditional γ-index

analysis are appropriate for the generalized method. Thus, we systematically determined the
proper magnitudes for all three criteria. Traditionally, γ-index criteria have been determined by
manual retrospective analyses of which criteria were achievable at a specified pass rate and

thresh (typically, 90% pass rate with thresh = 5% of Rx )63, 64. Although this method may be
used with 2G , we developed an algorithmic approach to determine the agreement criteria that
8

enables automation and reduces subjectivity. The algorithm determines the set of agreement
criteria corresponding to a specified passing rate. The ability to specify an arbitrary passing rate
is important because passing-rate requirements vary with the application, e.g., patient care,
epidemiological research, and dose-algorithm development.
Our algorithm for determining the 2G -index agreement criteria utilizes a systematic search for the
minimum agreement criteria magnitudes that result in the specified passing rate. This search was
performed using in-house code written in MATLAB (The MathWorks Inc., version R2016a,
Natick, Massachusetts, United States). The systematic search required two inputs: a
representative data set and the initial conditions for the search. The former is representative of
the dose-determination method (e.g., measurement, treatment planning system (TPS) calculation,
Monte Carlo simulation, etc.) to which the agreement criteria will be applied. The latter is a set

of agreement criteria that are so large such that the initial 2G passing rate surpasses the ultimately

specified passing rate. First, the code iteratively and monotonically reduced the agreement
criteria values by steps of 0.05 mm, 0.05%, and 0.05 mGy/Gy for  , R , and A ,

respectively. The code flagged all combinations of agreement criteria that resulted in the
specified passing rate or higher. Each flagged set of agreement criteria was assigned an overall
score according to,
∆ :
∆R,:
∆A,:
7=8
;×=
>×=
>
∆ min
∆R,min
∆A,min

where ∆ : , ∆R,: , and ∆A,: are the distance-to-agreement, relative-dose-difference, and

absolute-dose-difference criteria magnitudes in the ith set of flagged agreement criteria. ∆

2.6

min ,

∆R,min , and ∆A,min are the minimum magnitudes of each criterion amongst those in the list of
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all flagged combinations. Next, the list of scored sets of agreement-criteria triplets were sorted in
order of ascending score. The final result was the set of agreement criteria with the lowest score.
In addition to these three criteria, the 2G -index method requires the user to select thresh (See Eq.
2.1). This threshold was represented as a percentage of Rx . Following current clinical practice,

we used thresh = 5% of Rx . To confirm that our results were insensitive to our selection of

thresh , we additionally calculated passing rate as a function of thresh .
2.2.3. Demonstration of New Methods

In order to demonstrate the new 2G -index method, we performed an example of the analysis

method in two steps. First, we demonstrated the use of our algorithm for determining 2G -index
agreement criteria for a set of measured and calculated dose profiles. Second, we used the new

2G -index method to perform three example evaluations: one 1-dimensional comparison of dose
profiles (independent from those used in determining the agreement criteria), one 2-dimensional
comparison of dose planes, and one 3-dimensional comparison of dose volumes. In each case,
we performed both traditional- and generalized-gamma-index analyses. We designed this
demonstration to be of relevance to clinical, research (e.g., epidemiological studies), and
development (e.g., dose-algorithm development) applications. The following sections contain
details on each of these steps and the data used for this demonstration.
2.2.3.1 Determination of Agreement Criteria.
We used the systematic-search algorithm (see Section 2.2.2) to find the agreement criteria
corresponding to four specified passing rates (100%, 95%, 90%, and 67.5%). The 100% passing
rate corresponds to the agreement criteria that accommodate the maximum discrepancy between
reference and test dose magnitudes, i.e., all data agree within these criteria. The 90% pass rate is
commonly used to evaluate clinical therapeutic dose distributions42. Finally, 95% and 67%
10

passing rates conveniently correspond to 2-? and 1-? confidence intervals, respectively. The

initial guesses of agreement criteria were  of 50 mm, # of 10%, and * of 20 mGy for the

pass rate of 100% (2G -index analysis confirmed a 100% 2G passing rate). The initial guesses for
the searches at the next lower passing rate were the resulting agreement criteria from the next
larger passing rate (e.g., initial guesses for a systematic search for criteria corresponding to a
95% passing rate were the results of the search for a 100% passing rate, etc.).
2.2.3.2 Example Gamma-Index Evaluations

Table 2.1 contains the agreement criteria, thresh , and test passing rate used for 1-, 2-, and 3-

dimensional γ- and 2G -index evaluations. It should be noted that traditional γ-index comparisons
used only # ,  , and thresh , while the 2G -index comparisons additionally used A .

Table 2.1. Parameters for example gamma- and generalized-gamma-index evaluations.
Parameters include the agreement criteria (i.e., relative dose difference, # , absolute dose
difference, A , distance to agreement,  ), threshold dose, thresh , and the test passing rate.
# [%]
A [mGy]1  [mm] thresh [%] Test Passing
Rate [%]
1-D
3.0
0.8
3.0
5.0
≥90
2-D
4.6
0.8
0.5
5.0
≥90
≥90
3-D
3.0
0.8
3.0
5.0
1
used for 2G -index comparisons only
2.2.3.3 Reference and Test Absorbed Dose Distributions.
We acquired the data for this study by four methods: measurement, treatment-planning-system
calculation, Monte-Carlo simulation, and analytical-model calculation. Measured dose profiles
were previously published by Kaderka et al.65 The measurements utilized in this study were
performed on an electron linear accelerator (Elekta SL25, Stockholm) equipped with an MLCi2
at Universitätsklinikum (KGU) in Frankfurt, Germany operated at 6 MV. Kaderka et al.
measured photon doses to a distance of 40 cm from the beam central axis (CAX) with a 1.03-mm
spatial resolution using a diamond detector (60003 PTW, Freiburg) in a water-tank phantom
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(PTW, Freiburg) and reported a maximum relative uncertainty of 9%. These data were used as
the reference data in the systematic search for appropriate agreement criteria and in the γ- and

2G -index evaluations of a 1-dimensional absorbed dose profile.

We used one commercial TPS (Eclipse, Varian Medical Systems, Palo Alto, CA) and one
research TPS (CERR)66 in this study. The commercial TPS was commissioned for the electron
linear accelerator (Elekta Synergy, Stockholm) equipped with an MLCi2 at Mary Bird Perkins
Cancer Center in Baton Rouge, Louisiana and provided the test data for the 1-dimensional
evaluations. Prior to these evaluations, we took steps to confirm that the commercial TPS was
suitably commissioned for calculating beams from the treatment unit measured by Kaderka et al.
for the purposes of this manuscript (i.e., average dose difference of 1.5% and 0.4 mGy/Gy in the
high- and low-dose regions, respectively). The dose grid for these TPS calculations extended to a
distance of 40 cm from the beam CAX in the in- and cross-plane directions with a resolution of
0.5 x 0.5 x 0.5 cm3. The commercial TPS, however, only calculated non-zero dose magnitudes to
a distance of 16.5 cm from the beam CAX. Only this non-zero dose region was included in the
example comparison. The research TPS, CERR, provided the test data for the 3-dimensional
evaluations with a 1 x 1 x 1-cm3 grid resolution covering the entire imaged patient anatomy
(axial distance of 30 cm). Additionally, we created an extended version of CERR that includes
dose calculations in the low-dose region based on the analytical model of Schneider et al.67 This
extended version of CERR provided the reference data for the 3-dimensional evaluations with a
0.10 x 0.10 x 0.25-cm3 grid resolution also covering the entire imaged anatomy. The 3dimensional dose distributions were calculated for a single AP photon beam to the prostate in a
patient previously treated at our institution (Mary Bird Perkins Cancer Center, Baton Rouge).
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Monte Carlo simulations of absorbed dose were performed using the Monte Carlo N-Particle
eXtended (MCNPX) transport code version 2.768. The MCNPX model was designed based on
design information for an Elekta Precise medical linear accelerator equipped with an Agility
MLC provided by the manufacturer. The phantom used in the simulations was a homogeneous
water box measuring 120 cm x 120 cm in the plane perpendicular to the beam central axis
(CAX) and 30 cm deep in the plane parallel to the beam CAX. Photons and electrons were
transported and F6 lattice tallies for each particle type were used to determine the energy
deposited in each 1.0 x 1.0 x 1.0-cm3 voxel in the phantom extending to a distance of 20 cm from
the beam CAX in the in- and cross-plane directions. We utilized high-performance-parallelcomputing resources at Louisiana State University to simulate 109 electrons on target on 256
CPU-cores resulting in an average statistical fluctuation of 6.9%. These data were used for the
reference dose plane in the 2-dimensional comparison.
We used an analytical absorbed dose model40, 67 to generate the test data for both the

determination of appropriate agreement criteria and the 2-dimensional γ- and 2G -index

evaluations. This model was previously trained and validated for an Elekta SL25 medical linear
accelerator (see above) with a reported average uncertainty of 9.9%67. We used this model to
calculate absorbed dose with a spatial resolution of 0.1 cm to a distance of 50 cm from the beam
CAX.
Table 2.2 lists the configuration details for all reference and test data sets used in this study.
Different sources of reference and test data were used for each comparison to provide
representative examples of a variety of research and future clinical applications of the
generalized-gamma-index method. The example agreement-criteria determination is
representative of using this method in the research setting to characterize the accuracy of a new
13

dose-calculation algorithm. The one-dimensional evaluation provides a representative example
of a possible future clinical application of this method to compare measurements and commercial
TPS calculations. The two-dimensional evaluation is representative of using this method in the
research setting to test the accuracy of an analytical model during algorithm development.
Finally, the three-dimensional example is representative of a research application of this method
to the clinical translation and commercialization of a new dose-calculation algorithm. Figure 2.1
shows a representative example of reference and test data used in the systematic search for
appropriate agreement criteria. Figure 2.2 shows the reference and test dose distributions used
for 1-, 2-, and 3-dimensional γ- and 2G -index analyses.

Table 2.2. Configuration for all reference and test data used for the demonstration of generalizedgamma-index methods. Details include the square field size, source-to-surface distance (SSD),
depth in water, profile orientation (in plane or cross plane), and the source of data.
Agreement Criteria Determination
Orientation
Source of
Reference Data
In-Plane Profile
Measurement65

Field Size
(cm2)
5x5

SSD
(cm)
100

Depth
(cm)
1.5

5x5

100

1.5

Cross-Plane Profile

Measurement65

5x5

100

10

In-Plane Profile

Measurement65

10x10

100

1.5

In-Plane Profile

Measurement65

10x10

100

1.5

Cross-Plane Profile

Measurement65

Example Evaluations
Cross-Plane Profile
Measurement65

10x10

100

1.5

10x10

100

1.5

2-Dimensional Plane

6.5x6.5

94.8

N/A

3-Dimensional
Volume
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Monte Carlo (This
work)
Extended CERR
(This work)

Source of Test
Data
Analytical
Model40
Analytical
Model40
Analytical
Model40
Analytical
Model40
Analytical
Model40
Commercial TPS
(This work)
Analytical
Model67
CERR66

Figure 2.1. Representative example of reference and test profiles for the systematic search for
appropriate agreement criteria. Absorbed dose, D, versus off-axis distance, x, for a 10x10 cm2, 6MV photon field at a depth of 1.5 cm in a homogeneous water-box phantom in the cross-plane
direction. Reference data were measured65 and test data were calculated using an analytical
model40 (See Table 2.2).
2.3. Results
2.3.1.

Determination of Agreement Criteria

Using the systematic-search method described in Section 2.2.2, we found the agreement criteria
listed in Table 2.3. These results show that the appropriate agreement criteria are generally
sensitive to the selected passing rate. More specifically, the magnitudes of the agreement criteria
are inversely related to the passing rate. The information contained in Table 2.3 demonstrates the
advantages of the systematic-search method over a priori user-selection of criteria; namely that
the passing rate may be largely an artifact of the subjectively selected criteria. Thus, a priori
selection provides limited information on algorithm performance. By the proposed method, one
may obtain a more complete picture of the performance envelope of the algorithm in question.
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Figure 2.2. Reference and test data used for gamma- and generalized-gamma-index analyses in 1,
2, and 3 dimensions.
Table 2.3. Agreement criteria found by the systematic search for four selected passing rates.
Results are based on the analysis of data listed in the top section of Table 2.2 and plotted in
Figure 2.1. Criteria include distance to agreement ( ), relative dose difference (R ), and
absolute dose difference (A ).
Passing
 (mm) R (%) A (mGy)
Rate
100%
3.7
9.1
9.6
95%
1.0
5.2
1.6
90%
0.5
4.6
0.8
67.5%
0.5
1.6
0.2
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2.3.2.

Example Evaluations

Table 2.4 lists the passing rates for 1-, 2-, and 3-dimensional γ- and 2G -index evaluations. Each

of these reference and test data pairs contained known discrepancies outside of the therapeutic

treatment field due to clinically-realistic errors. Discrepancies in the 1- and 3-dimensional dose
distributions resulted from the significant underestimation of stray dose by the treatment
planning systems38-41. These discrepancies were so severe and widespread in the 3-dimensional
dose distributions that only 1.05% of the low-dose region passed the generalized-gamma-index
analysis. This, combined with the fact that the low-dose region comprised 93% of the total
volume considered, resulted in the strikingly lower 2G -index passing rate for this test.

Discrepancies in the 2-dimensional dose distribution resulted from the fact that we calculated the
reference and test dose distributions for different treatment machines with different MLC models
(See Section 2.2.3.3). γ-index analysis only looks at the region where  ≥ thresh , rendering
it insensitive to these discrepancies. This led to test results of “pass” in each case, despite the
discrepancies. 2G -index, on the other hand, looks at the entire dose distribution and correctly

resulted in a passing rate considerably lower than 90% and a “fail” of all three tests.

Table 2.4. Passing rates for gamma- and generalized-gamma-index analyses. See Table 2.1 for
corresponding test criteria.
Traditional Gamma Index
Generalized Gamma Index
Evaluation
γ Passing Rate Test Result
γG Passing Rate
Test Result
1-dimensional
100%
Pass
55.4%
Fail
2-dimensional
97.8%
Pass
44.5%
Fail
3-dimensional
96.4%
Pass
8.9%
Fail
2.4. Discussion
We developed a generalized gamma-index-analysis method in 1-, 2-, and 3-dimensions. The

major finding of this study is that the proposed 2G -index method provides a reliable and objective
assessment of the agreement of distributions spanning three orders of magnitude in absorbed
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dose. In particular, this new method correctly characterized dosimetric errors in the lowest dose
region, which are excluded by traditional γ-index methods60-62. We also proposed a method for

objectively determining the appropriate 2G -index agreement criteria at any specified passing rate
using an algorithmic approach. This new method comprises a more systematic approach with
lowered requirements for user skill and subjective judgement.
Traditional γ-index analysis methods exclude all dose magnitudes <5% of Rx . Our study

suggests that it is possible to evaluate the accuracy of dose distributions spanning multiple orders
of magnitude with a single, universal method. The proposed 2G -index method could find use in a
variety of scientific and development applications. For example, to study the long-term side
effects of radiotherapy treatments, radiation epidemiologists require methods to calculate the
absorbed dose everywhere in the patient, not just in the therapeutic dose region. Moreover, an
understanding of the uncertainties associated with these dose magnitudes can be just as important

in these studies as the doses themselves. Thus, the proposed 2G -index method could find utility in
developing and benchmarking the required dose algorithms. Additionally, the method for the

objective determination of 2G -index agreement criteria enables a more complete description of
the envelope of agreement, elucidating vital information about the associated uncertainties.
Our findings are in good agreement with previous γ-index studies in the literature. Nelms et al.62
and Zhen et al.61 studied the sensitivity of passing-rate to patient dose errors for 2- and 3dimensional γ-index analyses, respectively. In each of these studies, the authors simulated
increased and decreased MLC transmission in a dose calculation and assessed whether traditional
gamma-index methods were sensitive to these errors. Nelms et al. concluded that there was no
correlation between γ passing rates and the introduced errors while Zhen et al. found negligible
to weak correlations. Much like these previous studies, the MLC transmission differed between
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our reference and test 2-dimensional dose distributions. Similarly, our traditional γ-index test still
passed despite these errors, adding to the growing body of evidence showing the insensitivity of
traditional γ-index analysis to dosimetric errors outside of the therapeutic treatment field60-62.
In this study, we showed for the first time that it is possible to simultaneously evaluate high- and
low-dose regions of a dose profile spanning three orders of magnitude using a universal method.
The major strength of this study was that it utilized the well-established and widely used γ-index
analysis at doses above the threshold dose level, providing coherence with previous works and
consistency with current clinical practices. Another strength of this study is that it demonstrated
evaluations of 1-, 2-, and 3-dimensional dose distributions in both simple (i.e., water-box
phantom) and clinically-realistic geometries.
This study has several limitations. One limitation is that we only demonstrated the new method
on single-field, conventional dose distributions. This is not a serious limitation because a study
by Nelms et al. found that the majority of clinics perform field-by-field analysis in patientspecific quality assurance tests rather than composite analysis42. Further, the purpose of this
work was to develop and demonstrate the ability of the new method to overcome limitations of
hitherto methods, not to conclusively characterize any particular dose distribution. Future work,
however, should examine the application of the proposed method to additional treatment types
(e.g., IMRT, etc.) and for measurements taken in other QA phantoms (solid water,
anthropomorphic phantom, etc.).
2.5. Conclusion
The new method developed in this study enables the analysis of 1-, 2-, and 3-dimensional dose
distributions across three decades of absorbed dose. Additionally, we proposed an objective,
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algorithmic procedure for determining the appropriate agreement criteria, e.g., relative and

absolute dose difference and distance to agreement. The demonstration of the 2G analysis method

revealed that the new 2G method is capable of simultaneously evaluating the agreement of dose

distributions spanning three orders of magnitude in both high- and low-dose regions. Moreover,
the results were insensitive to the user-selected thresh .

Recent interest in understanding and mitigating the long-term side effects of radiotherapy
treatments has led to the emergence of numerous whole-body-dose calculation methods, such as
analytical algorithms and Monte Carlo simulations. A standardized method of meaningfully
assessing dosimetric accuracy throughout the whole human body (i.e., high- and low-dose
magnitudes) is required to assess and compare the accuracy of these dose algorithms. The
generalized-gamma-index method proposed here could initially find utility in a variety of
research applications including dose algorithm development and translation, as well as in
epidemiological studies on radiation toxicities. Furthermore, continued interest in improving
long-term patient health outcomes will likely lead to the clinical implementation of such dose
algorithms, at which point this same method could also be applied to clinical tasks including
patient-specific quality assurance and machine commissioning.
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Chapter 3. Method to Quickly and Accurately Calculate Absorbed

Dose from Therapeutic and Stray Photon Exposures throughout
the Entire Body in Individual Patients
3.1. Introduction
Increasing cancer survival rates in the United States have created a large and growing population
of cancer survivors, which is expected to number over 20 million in the next decade10.
Epidemiological research on this population has revealed that the majority of long-term cancer
survivors are at a heightened risk for health complications as a result of their primary disease
and/or treatment7, 69. Nearly two-thirds of these survivors will have received radiation therapy as
a part of their care11 and the vast majority of these radiotherapy treatments will have been
performed with megavoltage photon therapy70. Photon treatment techniques typically devote
considerable attention to limiting the exposure of healthy tissues outside of the intended
treatment volume71. Nonetheless, small levels of unwanted stray radiation reach the patient's
entire body, which increase the risk of late effects, including second cancer72, cardiac toxicity16,
and fertility complications17. Of these late effects, perhaps the most extensively studied is second
cancer73. Second malignancies occur most frequently outside of the volume treated for the
primary cancer with peak frequency in volumes which received < 2.5 Gy43.
Despite strong evidence of the importance of stray radiation to patient outcomes74, 75, commercial
Treatment Planning Systems (TPS's) significantly underestimate the total absorbed dose outside
of the therapeutic treatment field38-41, 76. Figure 3.1 shows a representative example of just how
poorly these doses are known clinically. The shaded area represents the region in which one
study observed nearly a quarter of all reported second malignant neoplasms43. This figure reveals
that the shaded area corresponds to the region where the commercial TPS's underestimate or
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neglect the absorbed dose. Thus, these exposures, and the risks they incur, are not explicitly
considered in the treatment-planning process.

Figure 3.1. Dosimetric limitations of commercial treatment planning systems. Total absorbed
dose (D) versus distance from the beam central axis (x) from two contemporary commercial
TPS’s compared to measurements. Measurements and calculations are for a 5x5 cm2, 6-MV
photon field at 10-cm depth in a water-box phantom at 100 cm source-to-surface distance. The
grey-shaded region represents the region in which Diallo et al. observed 22% (25 of 115) of
reported second cancers43.
This has led to the emergence of numerous alternative methods for quantifying out-of-field doses
from photon radiotherapy including measurements65, 77, Monte Carlo simulations46, 52, 78, and
analytical models40, 46, 47, 74, 75, 79-81. Of these, measurements are considered the gold standard in
accuracy. However, the time required for obtaining high-quality, patient-specific measurements
render this method impractical for routine clinical implementation. Monte Carlo dose models are
the most physically realistic and dosimetrically accurate of the calculation methods. This has
made them a popular tool for research groups focused on treatment planning using whole-body
dose calculations75, 82. Despite these clear advantages, complete Monte Carlo dose models tend to
be highly complex to develop and calibrate, a task which often requires proprietary information
regarding the radiation treatment machines. Furthermore, they require long computation times to
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converge on a solution and achieve acceptably low statistical fluctuations, especially outside of
the therapeutic treatment field. These and other factors decrease the feasibility of implementing
Monte-Carlo methods into the clinical treatment-planning workflow as a whole-body-dose
calculation tool. Analytical models, on the other hand, are comparatively simple and fast40. There
is also promising evidence suggesting they can be dosimetrically accurate in the out-of-field
region40, 49, 67, 75, 79, 83. Further, a recently published analytical model is readily generalizable to
different treatment machines and irradiation conditions without the need for proprietary
information due to its physics-based framework40, 67. It is not known, however, if such algorithms
could be implemented into a TPS to quickly and accurately predict the otherwise missing out-offield dosimetric information.
The purpose of this study was to test the feasibility of quickly and accurately calculating the total
absorbed dose to the whole body in individual patients receiving photon radiotherapy. To
accomplish this, we implemented a physics-based analytical dose model into a research TPS and
assessed the dosimetric accuracy by comparing results to measured total absorbed dose in waterbox and anthropomorphic phantoms. We also characterized the additional computation time
required for whole-body dose calculations.
3.2. Methods
In this study, we implemented a physics-based analytical model following the methods of
Schneider et al.67 into a TPS. For the reader's convenience, we briefly review the analytical
model (Section 3.2.1) before describing how we implemented it as an extension to the research
TPS (Section 3.2.2). We detail how we configured the extended TPS for calculating whole-body
doses from 6- and 15-MV photon radiotherapy exposures in a water-box phantom (Section 3.2.3)
and validated it in water-box (Section 3.2.4) and adult-male anthropomorphic phantoms (Section
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3.2.5). Finally, we describe methods to measure the computation time required for a whole-body
dose reconstruction using the extended TPS (Section 3.2.6).
3.2.1. Analytical Model for Total Absorbed Photon Dose
We modeled the total absorbed dose from therapeutic and stray photon sources during photon
radiotherapy, T , as the sum of four terms following Schneider, et al.67, or
T = P + HS + PS + L

3.1

where P denotes the primary therapeutic dose, HS is the dose from head-scattered photons, PS

is the dose from photons that scattered in the phantom or patient, and L is the dose from leakage
photons. Each term in Eq. 3.1 contained separate functions to characterize the photon attenuation
and scattering in the treatment unit and in the phantom or patient. This model was specifically
designed for ease and simplicity of configuration, (i.e., all configuration data can be quickly
measured in most clinics and proprietary information is not used). A complete description of the
model’s components and fitting parameters was given elsewhere67.
3.2.2. Implementation of the Analytical Model into a Research TPS
We implemented the analytical model for total absorbed dose from therapeutic- and stray-photon
radiation exposures (see Eq. 3.1) in the treatment-planning module of the Computational
Environment for Radiotherapy Research (CERR version 5.2)66 using MATLAB (The
MathWorks Inc., version 2014a, Natick, Massachusetts, United States), thus creating an
extended version of CERR henceforth referred to as CERR-LSU. To do this, we used a bridging
technique to combine the dose distributions from CERR and the analytical model into a single
CERR-LSU dose distribution.
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The bridging technique divided the exposed volume into three distinct regions: in-field, nearfield, and far-from-field. The in-field region comprised all locations where the dose calculated by
the TPS (in this case CERR) was ≥ 50% of the prescribed dose (Rx ). The far-from-field region

included locations where the total absorbed dose calculated by the TPS was ≤ 5% of Rx . The

near-field region included all remaining locations, or those locations where the TPS-calculated

dose was between 50% and 5% of Rx . Figure 3.2a shows a schematic illustration of these three
regions.

Figure 3.2. Schematic illustration of the bridging method to composite dose distributions from
two models. (a) Plot of the relative absorbed dose, D, versus position, x, where A is the location
at which Model I (i.e., CERR) reached the A relative-dose level (i.e., 50%) and B is the
location at which Model I reached the B relative-dose level (i.e., 5%). A separated the in- and
near-field regions and B discriminated between the near- and far-from-field regions (b) Plot of
weight given to Model I, W, versus position, x, corresponding to the example of the bridging
technique shown in panel (a) (see Eq. 3.3).
The dose matrix in CERR-LSU comprised three regions. Doses in the in-field region came from
CERR, those in the far-from-field region came from the analytical model, and doses in the near-
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field region were calculated as a weighted sum of the two dose calculations, as depicted in
Figure 3.2a. Algorithmically,
CERR-LSU = CERR × N + AM × @1 − NB

3.2

where CERR-LSU is the CERR-LSU dose, CERR is the dose calculated by CERR, AM is the dose
from Eq. 3.1 (i.e., T ) of the analytical model, and N is a weighting factor calculated by,
1
for CERR ≥ 50% × Rx

% − 5%
N = P8 CERR
; for 5% × Rx < CERR < 50% × Rx
50% − 5%
0
for CERR ≤ 5% × Rx

3.3

where all parameters are as previously defined. Figure 3.2(b) shows a representative example of
N.

3.2.3. CERR-LSU Configuration
We configured CERR-LSU to calculate the absorbed dose from a medical linear accelerator
(Elekta Precise, SN: 1605, Stockholm, Sweden) at the Physikalisch-Technische Bundesanstalt
(PTB) in Braunschweig, Germany (Electron Accelerator Facility, Dosimetry for Radiation
Therapy and Diagnostic Radiology, High-Energy Photon and Electron Radiation, Group 6.21).
The primary task in configuring CERR-LSU was to determine the magnitudes of the 28
empirical parameters in the analytical model. To do this, we followed the methods of Schneider
et al.67 and utilized a commercially available optimization toolbox (MATLAB version R2016a,
The MathWorks Inc., Natick, Massachusetts, United States) to perform a least-squares fit of the
analytical model to total-absorbed-dose profiles measured in a water-box phantom.
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Due to limitations of the documentation available on the research platform CERR, we were
unable to commission the treatment-planning module for our linear accelerator (i.e., to input
measured dose profiles). To overcome this limitation, we applied a multiplicative correction

factor (U) to the doses initially calculated by CERR, CERR,O , such that the corrected relative-

depth-dose curve on the beam central axis (CAX) matched the respective measured curve,

measured, for each field size. More specifically,

CERR , Z,  = CERR,O , Z,  × U 

3.4

CERR,O 0,0,  × U  = measured 0,0, ,

3.5

where CERR was the corrected dose (i.e., that used in Eqs. 3.2 and 3.3) and U was empirically
found such that

where,
4_
− 2 × 10\b ; ×
`
U=P
4_
82 × 10\] ×
+ 3 × 10\b ; ×
`
89 × 10\] ×

where

4_
+ 1; for 6-MV photon beams
`
4_
+ 83 × 10\c ×
+ 1; for 15-MV photon beams,
`
+ 8−1 × 10\c ×

3.6

was the depth in mm, and _ and ` were the collimated field area and perimeter in mm,

respectively, defined at isocenter.

Table 3.1 lists the measurement conditions used to configure the analytical model. We performed
all measurements in a 60x60x60-cm3 water-box phantom at a source-to-surface distance (SSD)
of 90 cm for 6- and 15-MV photon beams. We used a diamond detector (PTW TM60019 SN:
122240, Freiburg) for measurements in the in- and near-field regions to achieve high spatial
resolution in areas of steep dose gradient (e.g., the penumbra). The relatively lower signal in the
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far-from-field region necessitated a large-volume detector and thus we used a farmer-type
chamber (IBA FC65-G SN: 3068, Louvain-la-Neuve) for measurements in this region. We
corrected the measurements made with the diamond detector for dose-rate effects following the
methods of Laub et al.84 We corrected the farmer-chamber measurements for variations in
photon spectral fluence with measurement location following the methods of Chofor et al.85, 86
Table 3.1. Measurement conditions for the profiles used to configure and validate CERR-LSU in
a water-box phantom. Conditions include square field size, depth in water, scan direction, and
the purpose of the measurement (i.e., model configuration or validation). All profiles were
measured for 6- and 15-MV photon beams in a 60x60x60-cm3 water-box phantom at 90-cm SSD
using a diamond detector and a farmer chamber.
Depth in Water
Scan
Purpose
Field Size (cm2)
(cm)
Direction
2x2, 4x4, 10x10, 20x20
3.5, 10, 40
In plane
Configuration
”
”
Cross plane
”
”
Depth dose
”
2x2, 4x4, 10x10, 20x20
20
In plane
Validation
”
”
Cross plane
”
14x14, 20x5
3.5, 10, 20, 40
In plane
”
”
”
Cross plane
”
”
Depth dose
We performed two tests to characterize the dosimetric accuracy compared to the measurements
used to configure the model (see Table 3.1). First, we calculated the relative local dose

differences  R  in the in- and near-field regions and the absolute local dose differences  A 
in the far-from-field region for both CERR and CERR-LSU. From these, we calculated the
average, root-mean-square (RMS), median, and maximum local dose differences between
measured and calculated dose magnitudes. Second, we determined the appropriate generalizedgamma-index agreement criteria for CERR-LSU corresponding to four selected passing rates
(67.5%, 90%, 95%, and 100%) following the methods of Wilson et al.33 (see Chapter 2). The
generalized gamma index provides a universal method of assessing the dosimetric accuracy of
dose distributions spanning three orders of magnitude. It is calculated according to
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ΓG m , c  =


⎧   m , c  "# m , c 

+
, for m at in- and near-field locations
⎪
 
 
R

⎨    ,   "   ,  
m c
*
m c
⎪
+
, for m at far-from-field locations
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⎩

3.7

where   m , c  is the difference between measured, m , and calculated, c , locations,

respectively, (i.e., distance to agreement). "#  m , c  is the relative dose difference and

"*  m , c  is the absolute dose difference between measured and calculated dose magnitudes at
locations m and c , respectively.  , # , and * are the criteria of distance to agreement,

relative dose difference, and absolute dose difference, respectively. In-, near-, and far-from-field
regions are defined as in Section 3.2.2. A more complete description of this method and
examples of its use are given elsewhere33 (see Chapter 2).
3.2.4. Validation in a Water-Box Phantom

We validated the dosimetric accuracy of CERR and CERR-LSU calculations of 6- and 15-MV
photon-therapy beams in a water-box phantom by comparison to measurements. These
measurement conditions were intentionally distinct and different from those used to configure
CERR-LSU and are listed in Table 3.1. Specifically, we measured at different therapeutic field
sizes, aspect ratios, and depths in water compared to the configuration data. These measurements
utilized the same medical linear accelerator, water-box phantom, and detectors as previously
described (see Section 3.2.3). We characterized the dosimetric accuracy compared to
measurements for validation in a water-box phantom in a manner similar to that described in
Section 3.2.3. Specifically, the first test was the same. For the second test, we found the
generalized-gamma-index passing rates for CERR and CERR-LSU compared to validation

29

measurements following the methods of Wilson et al.33 (see Chapter 2 and Eq. 3.7). The
generalized-gamma-index agreement criteria for these comparisons were 4.5% relative dose
difference, 3.8 mGy/Gy absolute dose difference, or 1.25 mm distance to agreement.
3.2.5. Validation in Clinically Realistic Anatomy
In order to validate CERR-LSU in more clinically realistic anatomy, we delivered a 4-field-box
prostate treatment to an adult-male anthropomorphic phantom (ATOM® Adult Male model 701,
Computerized Imaging Reference Systems, Inc., Norfolk, Virginia). We chose to simulate a
prostate treatment because the location of the target volume near the lower end of the
anthropomorphic phantom placed several organs at risk (e.g., lens of eye, brain, etc.) at a large
distance from the target volume, thereby providing an extreme test of the extended TPS’s farfrom-field dosimetric accuracy. We selected a 4-field box treatment because the relative
simplicity of the treatment plan facilitated treatment planning and delivery in the research
setting. The treatment plan consisted of four 8x8-cm2 photon fields (i.e., anterior-posterior (AP),
posterior-anterior (PA), left lateral (LL), and right lateral (RL)) delivered isocentrically with
equal weights. We calculated the total absorbed dose from this treatment plan using both CERR
and CERR-LSU for 6- and 15-MV photons. Figure 3.3 shows representative examples of the
dose distributions from these calculations.
We compared the dose distributions calculated by CERR and CERR-LSU to measurements in
the anthropomorphic phantom. We delivered the treatment plan to the anthropomorphic phantom
using the same linear accelerator as was used for the water-box measurements (see Section
3.2.3). We measured the total absorbed dose from photons using thermo-luminescent dosimeters
(TLDs) placed at each of 39 locations in organs and tissues throughout the phantom spanning in-,
near-, and far-from-field regions (See Figure 3.3c). These dosimeters were composed of lithium
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Figure 3.3. Representative examples of dose calculations for validation in an anthropomorphic
phantom. Isocentric coronal slice of the anthropomorphic phantom with the color wash
representing the relative dose calculated by CERR (a) and CERR-LSU (b) for the 6-MV, 4-fieldbox prostate treatment plan. Results for the 15-MV calculations were qualitatively similar. Doses
were normalized using the dose at isocenter. Isodose lines provide the dose distribution in the
far-from-field region in greater detail. The crosses in panel (c) indicate the approximate TLDmeasurement locations in the anthropomorphic phantom.
fluoride TLD-100 rods and are suitable for measuring out-of-field photon dose87. We irradiated
the TLDs in three groups based on the expected dose to the TLD location (i.e., high, medium,
and low dose, see Table 3.2) in order to ensure that the dose delivered to each TLD was within
the calibrated range. Finally, we corrected the measurements for the changes in spectral photon
fluence with location using the methods of Chofor et al.85, 86
Table 3.2. Characteristics of each field delivered to the anthropomorphic phantom: anteriorposterior (AP), posterior-anterior (PA), left lateral (LL), and right lateral (RL). Details include
the number of monitor units delivered and the total planned absorbed dose to isocenter from all
four beams (Rx ).
Monitor Units Delivered
TLD
Measurement
AP
PA
LL
RL
Rx (Gy)
Group
High-dose
31.3
31.3
37.8
37.8
1
Medium-dose
626
626
755.1
755.1
20
Low-dose
6260 6260
7560
7560
200
We normalized the measured dose magnitudes using the planned dose at isocenter (Rx , see

Table 3.2) to obtain the measured relative-absorbed-dose magnitudes. We extracted the relative
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dose magnitudes calculated by CERR and CERR-LSU at locations corresponding to the TLDmeasurement locations. Finally, we characterized the dosimetric accuracy of CERR and CERRLSU compared to measurements in the anthropomorphic phantom using the methods described
in Section 3.2.4.
3.2.6. CERR-LSU Computation Time
In order to characterize the additional time required to calculate dose using CERR-LSU
compared to CERR, we recorded the system CPU-time at the beginning and end of dose
calculations. We quantified the total computation time for each system as the difference between
beginning and end times. We followed these methods for four selected field sizes incident on a
44x30x180 cm3 water-box phantom. We chose this phantom size to approximate the size of a
large adult human88. Field sizes included 2-, 5-, 10-, and 20-cm squares. We repeated these
methods for isotropic dose grids of 1- and 2-cm3 resolution to assess the impact of grid resolution
on computation time. We also performed calculations to four regions of interest that varied in
volume in order to assess the impact of grid size on the computation time. The smallest region of
interest approximated the size of a torso and the largest included the entire phantom (see Table
3.3).
Table 3.3. Regions of interest for characterizing the computation time of CERR-LSU compared
to CERR. Details include the x, y, and z dimensions (see Figure 3.3a for coordinate system) of
the region and the number of calculation points, N, included in each region at each grid
resolution.
N
3
x (cm) y (cm) z (cm)
1-cm grid
2-cm3 grid
b
44
30
60
8.5 × 10
1.1 × 10b
”
”
100
14 × 10b
1.9 × 10b
b
”
”
151
21 × 10
2.8 × 10b
”
”
180
25 × 10b
3.3 × 10b
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3.3. Results
3.3.1. CERR-LSU Configuration
Table 3.4 lists the analytical-model parameters obtained by fitting the analytical model to
measured dose profiles (see Table 3.1) following the methods of Schneider et al.67 Figure 3.4
shows a selection of representative examples of measured and calculated absorbed dose profiles
from the CERR-LSU configuration process. This figure reveals that, qualitatively, CERR-LSU
calculations accurately approximated measurements in all regions of dose (i.e., in-, near-, and
far-from field) for a variety of irradiation conditions.
Table 3.5 lists the results of the quantitative assessment of the dosimetric accuracy of CERRLSU configuration. These data show that CERR-LSU had equivalent or superior accuracy
compared to CERR in all regions of dose with the largest improvements in the out-of-field
region. The most pronounced improvements were measured by the median relative and absolute
dose differences (i.e., R and A , respectively), which decreased by factors of 2 and 50,

respectively. These data also show that the average dose discrepancies for CERR-LSU were
within ±1% in and near to the treatment field and ±1 mGy/Gy far from the field, indicating that
there were no sizable systematic discrepancies.
Table 3.6 lists the values of the generalized-gamma-index agreement criteria at four selected
passing rates found using the systematic-search methods of Wilson et al.33 These data show that
the appropriate ∆R and ∆ magnitudes for CERR-LSU at a passing rate of 90% were

comparable to those for contemporary commercial systems42.
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Table 3.4. Magnitudes of analytical-model parameters. Parameters found by training the model
to measurements of 6- and 15-MV photon beams using doses measured for the purpose of model
configuration, listed in Table 3.1.
Term in Eq. 3.1
Description
Symbol (units)
Magnitude
th
Dose 0 order coefficient
900
P (Primary)
_P (mGy/Gy)
Field-edge correction factor
1.02
̅P,0 (−)
0.29
Secondary collimator penumbral
?P,0 (cm)
width
Projection correction factor
0.95
lP −
Attenuation 0th order correction factor mμ,P −
0.69
st
-1
Attenuation 1 order correction factor oμ,P (MeV )
3.6× 10\
Dose 0th order coefficient
4000
HS (Head Scatter)
pHS (mGy/Gy)
Dose 1st order coefficient
723
2HS (mGy/Gy/MeV)
Source width parameter
4.25
lHS,0 (cm)
Projection correction factor
0.64
lHS −
-0.13
Attenuation 0th order correction factor mμ,HS −
Attenuation 1st order correction factor oμ,HS (MeV-1)
0.19
th
8586
PS (Patient Scatter) Dose 0 order coefficient
pPS (mGy/Gy)
st
Dose 1 order coefficient
-0.06
2PS (mGy/Gy/MeV)
Lateral width
15.0
lPS,0 (cm)
Projection correction factor
1.04
lPS −
Attenuation 0th order correction factor mμ,PS −
1.41
st
-1
Attenuation 1 order correction factor oμ,PS (MeV )
-9.1× 10\qr
Dose 0th order coefficient
10202
L (Leakage)
pL (mGy/Gy)
st
Dose 1 order coefficient
-0.03
2L (mGy/Gy/MeV)
340
Lateral width correction factor
lL,0 (cm)
Projection correction factor
0.86
lL −
Attenuation 0th order correction factor mμ,L −
1.71
Attenuation 1st order correction factor oμ,L (MeV-1)
-9.2× 10\s
Primary collimator 0th order
0.32
pPC −
coefficient
Primary collimator 1st order
2.2× 10\
2PC (MeV-1)
coefficient
Primary collimator location
22.5
̅PC (cm)
Primary collimator penumbral width
0.05
?PC,0 (cm)
3.3.1. Validation in a Water-Box Phantom

Figure 3.5 plots representative examples of absorbed dose calculated by CERR-LSU compared
to measurements for the purpose of validation in a water-box phantom (see Table 3.1). This
figure shows that, qualitatively, CERR-LSU accurately calculated the dose for field sizes, aspect
ratios, and depths in water that differed from those for which it was specifically configured.
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Figure 3.4. Representative examples of the results of CERR-LSU configuration. Relative dose
(D) versus distance from the beam central axis (x). Points represent measured dose magnitudes
and lines represent CERR-LSU calculations. Black-filled markers are located in the in-field
region, gray-filled markers are in the near-field region, and open markers are in the far-fromfield region. Note that profiles at a depth of 40 cm did not contain any points in the in-field
region because the depth was such that the dose on the CAX was below 50% of Rx . Absorbed
dose magnitudes for each profile are offset by factors of 10 for visual clarity.
Table 3.5. Dosimetric agreement as assessed by comparison to configuration data. Data include
the average, root-mean-square (RMS), median, and maximum dose discrepancies for relative
dose comparisons ( R ) in the in- and near-field regions and absolute dose comparisons ( A )
in the far-from-field region (see Section 3.2.2). Data are for calculations by CERR and CERRLSU compared to measurements of 6- and 15-MV photon beams in a water-box phantom for the
purpose of configuration (see Table 3.1).
In- and Near-Field Regions
Far-from-Field Region
R (%)
A (mGy/Gy)
CERR
CERR-LSU
CERR
CERR-LSU
Average
-1.3
-0.81
-3.5
-0.32
RMS
5.0
5.0
7.5
3.7
Median
-0.84
-0.44
-1.1
-0.022
Maximum
37
36
58
35
Table 3.7 lists the results of the quantitative assessment of dosimetric agreement for validation in
water. These data reveal that CERR-LSU achieved superior accuracy to that of CERR in all
regions of dose. Furthermore, the mean, RMS, and median discrepancies for CERR-LSU in the
out-of-field region were similar to those in Table 3.5. This suggests that the accuracy in the out-

35

Table 3.6. Generalized-gamma-index agreement criteria for an interval of selected passing rates.
Agreement criteria include relative dose difference (∆R ), absolute dose difference (∆A ), and
distance to agreement (∆ ), and were determined based on comparisons to measurements of 6and 15-MV photon beams in a water-box phantom (see Table 3.1).
Passing Rate (%)
∆R %
∆A mGy/Gy ∆ mm
100
8.2
23.8
3.5
95
6.3
6.8
1.5
90
4.5
3.8
1.25
67.5
4.1
1.2
1.0
of-field region was not sensitive to changes in treatment configuration and provides evidence of
CERR-LSU’s high level of adaptability to different treatment configurations. The generalizedgamma-index passing rate for CERR-LSU at criteria of 4.5% relative dose difference, 3.8
mGy/Gy absolute dose difference, or 1.25 mm distance to agreement was 90%. The generalizedgamma-index passing rate for CERR compared to the same measurements and at the same
agreement criteria was substantially lower at only 64%. These results indicate that CERR-LSU
passed the gamma-index analysis while CERR failed at the typical test requirement of a 90%
passing rate42.
3.3.1. Validation in Clinically Realistic Anatomy
Figure 3.6 plots a representative example of the measured and calculated cephalocaudal profiles
from the validation of CERR and CERR-LSU in an anthropomorphic phantom. Dot-dashed lines
show the 1-σ confidence interval in CERR-LSU calculations, i.e., the interval containing 67.5%
of measurements. This figure clearly demonstrates the improved dosimetric accuracy of CERRLSU compared to CERR in the far-from-field region. Table 3.8 lists the absorbed-dose
magnitudes measured by TLD, calculated by CERR-LSU, and calculated by CERR at each of the
39 TLD locations for 6- and 15-MV irradiations. These data indicate that the largest
discrepancies were in and near boney structures (e.g., femoral heads and spinal cord) and near to
the field edge (e.g., rectum and bladder).
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Figure 3.5. Representative examples of dosimetric validation of CERR-LSU profiles in a waterbox phantom. Relative absorbed dose (D) versus distance from the beam central axis (x). Points
represent measured absorbed dose and lines represent CERR-LSU calculations. Black-filled
markers are located in the in-field region, gray-filled markers are in the near-field region, and
open markers are in the far-from-field region. Note that profiles for small field areas and at deep
depths did not contain any points in the in-field region (i.e., the relative dose on the CAX was
below 5% of Rx ). Absorbed-dose magnitudes for different profiles are offset by factors of 10 for
visual clarity.
Table 3.7. Dosimetric agreement as assessed by comparison to data for validation in a water-box
phantom. Data include the average, root-mean-square (RMS), median, and maximum dose
discrepancies for relative dose comparisons ( R ) in the in- and near-field regions and absolute
dose comparisons ( A ) in the far-from-field region (see Section 3.2.2). Data are for calculations
by CERR and CERR-LSU compared to measurements of 6- and 15-MV photon beams in a
water-box phantom for the purpose of validation (see Table 3.1).
In- and Near-Field Regions
Far-from-Field Region
R (%)
A (mGy/Gy)
CERR
CERR-LSU
CERR
CERR-LSU
Average
-0.79
-0.068
5.1
0.53
RMS
2.9
2.6
9.2
4.6
Median
-0.56
-0.14
-2
-0.053
Maximum
16
15
48
50
Table 3.9 lists the results of the quantitative assessment of dosimetric agreement for validation in
an anthropomorphic phantom at 6- and 15-MV photon-beam energies. These data show that
CERR-LSU achieved markedly better accuracy than CERR in the anthropomorphic phantom.
The improvement in dosimetric accuracy was especially pronounced in the far-from-field region
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Figure 3.6. Representative example of the results of validation in an anthropomorphic phantom.
Relative absorbed dose (D) versus cephalocaudal distance from isocenter (z) for 6-MV
measurements and calculations (see Figure 3.3a for coordinate system). Findings for 15 MV
were comparable. Measurement error bars represent 1-σ uncertainties. We estimated the
dosimetric uncertainty (i.e., vertical error) following the methods of Kry et al.87 We estimated
horizontal error bars as the uncertainty in TLD location resulting from positioning uncertainties
following the methods of Topolnjak et al.89
Table 3.8. Values of the absorbed dose measured by TLD, calculated by CERR-LSU, and
calculated by CERR for the validation in an anthropomorphic phantom. The listed organ
locations for each TLD are approximate (see Figure 3.3c).
Relative Dose (mGy/Gy)
6 MV
15 MV
Phantom
CERRCERRTLD Location
Slice
Measured
LSU
CERR
Measured
LSU
PTV (Isocenter)
34
960
990
990
980
990
PTV (Patient L)
34
970
980
980
980
980
PTV (Patient R)
34
970
970
970
980
980
Femoral Head
34
530
510
460
530
510
(R)
Femoral Head
34
510
440
430
520
450
(L)
Rectum
33
720
950
950
700
960
Rectum
32
140
52
16
130
52
Bladder
32
83
50
19
96
50
Bladder
32
74
48
20
70
48
(table cont’d.)
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CERR
990
980
980
470
430
960
16
18
19

Relative Dose (mGy/Gy)
TLD Location
Bladder
Bladder
Bladder
Spinal cord
Kidney (L)
Kidney (R)
Stomach
Liver
Chest (skin)
Chest (skin)
Chest (skin)
Lung
Lung
Lung
Lung
Lung
Lung
Heart
Thyroid
Brain stem
Lens of eye (R)
Lens of eye (L)
10 cm Superior
to Isocenter
15 cm Superior
to Isocenter
20 cm Superior
to Isocenter
35 cm Superior
to Isocenter
40 cm Superior
to Isocenter
45 cm Superior
to Isocenter
55 cm Superior
to Isocenter
60 cm Superior
to Isocenter

Phantom
Slice
Measured
32
120
32
45
31
34
29
3.3
26
3.3
26
3.2
24
2.2
22
1.1
19
0.90
19
0.73
19
0.86
18
0.30
18
0.30
18
0.53
18
0.53
13
0.50
13
0.50
14
0.30
10
0.20
5
0.18
5
0.26
5
0.25
31
42

6 MV
CERRLSU
53
53
26
11
3.7
3.7
1.8
0.99
0.63
0.63
0.64
0.39
0.39
0.49
0.50
0.51
0.52
0.37
0.35
0.33
0.33
0.28
30

CERR
16
17
0.28
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.38

15 MV
CERRMeasured
LSU
130
53
38
53
25
26
9.1
11
3.0
3.7
3.0
3.7
2.3
1.8
1.2
1.0
0.98
0.63
0.73
0.63
1.0
0.64
0.45
0.39
0.44
0.39
0.69
0.50
0.68
0.50
0.63
0.52
0.62
0.52
0.45
0.37
0.34
0.35
0.36
0.33
0.26
0.33
0.26
0.28
35
30

CERR
17
17
0.18
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.23

28

8.5

8.2

0

6.9

8.2

0

26

4.2

4.1

0

3.8

4.0

0

20

0.72

0.58

0

0.86

0.59

0

19

0.58

0.49

0

0.74

0.49

0

16

0.38

0.39

0

0.56

0.40

0

12

0.24

0.36

0

0.37

0.36

0

10

0.20

0.35

0

0.34

0.35

0

where CERR-LSU achieved a median A nearly 26 times smaller than that of CERR.

Furthermore, CERR-LSU achieved agreement in an anthropomorphic phantom similar to that in
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a water-box phantom (see Table 3.7). This indicates that the accuracy was not sensitive to the
presence of clinically realistic anatomy (i.e., surface irregularities and tissue heterogeneities).
Table 3.9. Dosimetric agreement as assessed by comparison to absorbed dose measured in an
anthropomorphic phantom. Data include the average, root-mean-square (RMS), median, and
maximum dose discrepancies for relative dose comparisons ( R ) in the in- and near-field
regions and absolute dose comparisons ( A ) in the far-from-field region (see Section 3.2.2).
Data are for calculations by CERR and CERR-LSU compared to measurements of 6- and 15-MV
photon beams in an anthropomorphic phantom (see Section 3.2.5).
In- and Near-Field Regions
Far-from-Field Region
R (%)
A (mGy/Gy)
CERR
CERR-LSU
CERR
CERR-LSU
Average
-2.3
-0.3
-4.4
0.2
RMS
10
9.0
10
3.2
Median
-5.9
-2.4
-0.70
-0.027
Maximum
26
26
42
15
The generalized-gamma-index passing rate for agreement criteria of 4.5% relative dose
difference, 3.8 mGy/Gy absolute dose difference, or 1.25 mm distance to agreement was 81%.
The generalized-gamma-index passing rate for CERR comparisons to TLD measurements in the
same anthropomorphic phantom and at the same agreement criteria was considerably lower at
only 8%. These results provide further evidence of the improved dosimetric accuracy of CERRLSU compared to CERR. Figure 3.7 plots the generalized-gamma-index results for both CERR
and CERR-LSU analyses versus the measurement point’s cephalic distance from isocenter.
These plots clearly show that CERR and CERR-LSU had comparable agreement in the in- and
near-field regions while CERR-LSU performed better than CERR in the far-from-field region.
More specifically, Figure 3.7a reveals that CERR-LSU performed better far from the treatment
field than in and near to the treatment field. Figure 3.7b, on the other hand, shows that CERR
performed best in the treatment field and failed at all far-from-field locations. This indicates that
CERR-LSU was limited by its dosimetric accuracy in the in- and near-field regions (i.e., by
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doses supplied by CERR) while CERR was limited by its dosimetric accuracy in the far-fromfield region.

Figure 3.7. Results of the generalized-gamma-index analysis in an anthropomorphic phantom.
Generalized-gamma-index magnitudes, uv , versus the measurement cephalic distance from
isocenter, z, for (a) CERR-LSU and (b) CERR compared to 6- and 15-MV TLD measurements in
an anthropomorphic phantom (see Figure 3.3a for coordinate system). The horizontal solid line
separates passing and failing generalized-gamma-index magnitudes.CERR-LSU Computation
Time
Figure 3.8a shows a representative example of the results of the timing characterization for
CERR and CERR-LSU. This figure reveals that the computation time for both systems increased
with increasing therapeutic field size and number of calculation points. Figure 3.8b plots the
CERR-LSU computation time relative to that for CERR and shows that CERR-LSU required
less than 1.3 times the computation time of CERR for all field sizes and regions of interest
studied. On average, CERR-LSU required 7% longer than CERR to additionally calculate the
absorbed dose from stray radiation exposures. Figure 3.8b also shows that the additional
calculation time required by CERR-LSU decreased with increasing therapeutic field size and
number of calculation points.
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Figure 3.8. Representative example of the characterization of computation time. (a) Computation
time, t, in CPU-s versus the number of calculation points, N, for four square field sizes at a 2-cm3
grid resolution. Filled markers represent CERR-LSU while open markers are for CERR. CERR
calculation times are offset by 500 calculation points for visual clarity. (b) Relative timing, wRel ,
versus the number of calculation points, N, at a 2-cm3 grid resolution where wRel is defined to be
x
the ratio of computation times for CERR-LSU to CERR or, CERR-LSU . Results for a 1-cm3
calculation-grid resolution were qualitatively similar.

xCERR

3.4. Discussion
In this study, we integrated a physics-based analytical model for the total absorbed dose,
including that from stray photons, into a TPS. We configured and validated the system, CERRLSU, for 6- and 15-MV photon beams using measurements in water-box and anthropomorphic
phantoms. The major finding of this work is that it does appear to be feasible to accurately and
quickly calculate the total absorbed dose from both therapeutic and stray photons in individual
patients as part of a routine treatment-planning process. The specific results of this study
revealed a sizable improvement in accuracy in the out-of-field region for calculations by CERRLSU compared to CERR. For example, we reduced the uncertainty in out-of-field dose to less
than 0.5 mGy/Gy at a distance of 30 cm from the beam CAX versus 20 mGy/Gy for CERR at the
same location. We expect this improvement in dosimetric accuracy to pertain to commercial
TPS’s as well. Figure 3.9 shows a representative example of the measured total absorbed dose
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along with confidence intervals corresponding to the 1-σ uncertainty in dose calculations by
commercial TPS’s and CERR-LSU. This figure clearly demonstrates the improvement of
dosimetric accuracy in the far-from-field region by CERR-LSU compared to the commercial
systems considered in this study. Furthermore, this improved dosimetric accuracy was possible
with an average increase in computation time of only 7%.

Figure 3.9. 1-σ confidence intervals for commercial-TPS and CERR-LSU dose calculations.
Relative absorbed dose (D) versus distance from the beam central axis (x). Measured dose
corresponds to a 10x10 cm2, 6-MV photon beam at a depth of 10 cm in water.
The implication of these findings is that treatment planning systems should include these or
similar algorithms to accurately predict stray radiation exposures. Knowledge of these exposures
is a requisite step in risk projection and the optimization of patient health outcomes (as in Wilson
et al.36, see Chapter 5). Similarly, the creation of personalized survivorship care plans will
require complete exposure data. Additionally, the routine availability of out-of-field doses could
simplify the treatment of patients with implanted electronic devices, such as pacemakers and
defibrillators. For these patients, it is necessary to estimate the dose to the device, even when it is
far from the treatment field, in order to avoid potential device malfunctions90. Similarly, these
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capabilities could find application to treatment planning for patients requiring retreatment for a
recurrence or second primary cancer. In these cases, ensuring that the cumulative dose to healthy
tissues remains at safe levels necessitates detailed reconstructions of the dose delivered by the
initial treatment, even at far distances from the initial target volume. Such reconstructions could
be readily calculated using an extended system, like the one developed in this work. Finally, such
an extended system could find use in large-scale epidemiology studies on radiation-related health
effects. Currently, the majority of such studies combine two or more dose-reconstruction
methods in order to meet requirements of speed and accuracy in therapeutic and stray-dose
calculations75. A tool like the one developed in this work could greatly simplify and streamline
the dose-reconstruction process, including recording the exposures into the electronic medical
record, and facilitating the continued development and refinement of risk models.
Our findings are consistent with others in the literature. In the most closely related study, Eley et
al.83 implemented an analytical model for leakage-neutron equivalent dose into a proton
radiotherapy treatment planning system. Their extended system increased the computation time
by 60%, which is on the same order of magnitude of our maximum estimate of the additional
time required for therapeutic and stray photon dose calculations of 30%. Wang and Ding
assessed the accuracy of out-of-field dose calculations of a model-based algorithm in a
commercial TPS. Their out-of-field discrepancy was on the same order of magnitude as ours
(i.e., theirs ranged from 3 to 5 mGy/Gy versus our 1 mGy/Gy). Schneider et al.67 previously
reported on the analytical model implemented in this work. In the previous study, Schneider et
al. trained the model to measurements in a water-box phantom from another Elekta medical
linear accelerator for three nominal photon beam energies (i.e., 6, 18, and 25 MV). Their average
unsigned dosimetric discrepancy with the measurements used to train the model was similar to
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ours (9.9% versus CERR-LSU’s 3.5%). In another study, Taddei et al. developed an empirical
analytical model for the stray dose from photon therapy79. They reported an RMS deviation from
out-of-field measurements in an anthropomorphic phantom of 0.91 cGy/Gy, which is on the
same order of magnitude as that of CERR-LSU under comparable conditions, namely, 0.32
cGy/Gy. Hauri et al. developed an analytical model for the stray dose from 6-MV photon therapy
and validated their model with TLD measurements of a 4-field-box prostate treatment in an
anthropomorphic phantom91. We found a similar mean dose discrepancy between measurements
and calculations in the far-from-field region, i.e., 8.5% in this work and 9% in Hauri et. al.
This study has several notable strengths. First, our approach utilized a non-proprietary, physicsbased analytical algorithm to quickly and accurately calculate the of out-of-field doses67.
Physics-based algorithms are more readily adaptable to other treatment units and modalities than,
for example, purely empirical models. This study also included high-quality data measured at a
national standards laboratory. These measurements spanned a wide range of irradiation
conditions and enabled an extensive validation of CERR-LSU in water-box and
anthropomorphic phantoms.
This study has several limitations. First, we only configured and validated CERR-LSU for
conventional photon therapy. This was not a serious limitation because extension to more
complex contemporary treatment deliveries, such as intensity-modulated radiotherapy (IMRT), is
possible. Indeed, this challenging task is underway in our laboratory and elsewhere. Another
limitation is that we only included stray dose from photons. Photon-beam energies above
approximately 8 MV also produce photo-neutrons, mainly in the high-Z components of the
treatment head. Our approach neglected these stray neutrons for the 15-MV irradiations. The
scope of this study was to incorporate the dose from stray photons. Numerous recent publications
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reported measurements and simulations of the photo-neutrons created during high-energy photon
therapy92-97 and models can be added to the presented framework when they are sufficiently
mature. Furthermore, there is ongoing work in our laboratory to develop another component of
this analytical model, specifically for dose from photo-neutrons. Preliminary results are
encouraging. We anticipate that implementation of a physics-based analytical neutron-dose
model could follow the same methods as those described above without having a large effect on
the computation time based on the findings of Eley et al.83 Another limitation is that the
analytical model used to predict stray dose, in its current form, neglects tissue heterogeneities
and surface irregularities. In spite of the current limitations of the extended TPS, we were still
able to achieve a vastly improved level of dosimetric agreement in the anthropomorphic phantom
(see Figure 3.6 and Figure 3.7).
3.5. Conclusions
The extended TPS developed in this study enables the quick and accurate calculation of
therapeutic and stray radiation exposures in individual patients. Our results provide promising
evidence that it may be feasible to routinely calculate whole-body doses, including therapeuticand stray-radiation exposures, in individual patients as part of the routine treatment-planning
process. This additional out-of-field dosimetric information could enable the personalized
consideration of radiotherapy late effects in both the treatment- and survivorship-care-planning
phases of the radiotherapy workflow. This in turn could lead to improved long-term health
outcomes for the growing population of cancer survivors, many of whom have received radiation
therapy.
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Chapter 4. Justification and Optimization of Planned Exposures: A New
Framework to Aggregate Arbitrary Detriments and Benefits
4.1. Introduction
The general principle of radiation protection comprises three pillars: justification, optimization,
and limitation98, 99. Justification refers to a planned radiation exposure’s ability to “produce
sufficient benefit to the exposed individuals or to society to offset the radiation detriment it
causes.”100 The pillar of optimization suggests that the radiation doses and number of exposed
people should be kept as low as reasonably achievable100. The final pillar, limitation, simply
states that the combination of all exposures should be subject to dose limits100. The pillar of
limitation is established by regulation and compliance is accomplished by administrative controls
(e.g., restricting access to radiation areas) and safety systems (e.g., safety interlocks on radiation
generators). Limitation is the most straightforward of the three pillars and compliance to limits
requires little subjective judgement. In contrast, justifying and optimizing planned radiation
exposures is generally more complex101-104 because of myriad radiation effects, including
benefits and detriments102, 105, 106. Consequently, justification and optimization commonly require
approximations, simplifications, assumptions, and subjective judgement.
The International Commission on Radiological Protection (ICRP), a leading advisory body in the
theory and application of radiation-protection principles, first proposed the application of costbenefit analysis for planned radiation exposures in 1973107. They noted, however, the difficulties
in applying such analyses to public and medical exposures. In fact, the ICRP explicitly excluded
the protection of patients from their consideration of medical exposures until the late 1960s,
based on an implicit assumption that the benefits to the patient outweighed any incurred risks108.
The current guiding principle behind recommendations of the ICRP, first proposed in 1990, is
the principle of “as low as reasonably achievable” or, ALARA109. The definition of reasonable in
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this context, however, is largely a matter of subjective judgement based on concepts, common
sense, wisdom, and field experience, rather than an objective judgement based on rigorous
analysis110.
Algorithmic methods of risk-benefit analysis are well established for planned medical exposures.
A seminal framework for this was proposed by Holthusen111 in 1936 using the probability of

uncomplicated tumor control (`y ). `y weighs the benefit against the short-term risk associated

with radiotherapy for cancer patients. In the eight decades that have followed, other researchers
have extended and modified `y for a variety of radiotherapy applications23, 25, 32. Yet, `y has

several important limitations, including that it neglects the risk of non-fatal detriments, which
may seriously impact the patient’s quality of life, as well as the risk of late-occurring detriments.
Other groups have suggested entirely different algorithmic methods of performing radiotherapy
risk-benefit analyses, most of which also only consider the patient’s short-term health effects22,

24, 27, 28

. Only since 2015 have studies taken the late-occurring health effects into account29-31, 112.

All of these methods, however, were developed to evaluate the special case of patients receiving
radiotherapy exposures, not for those receiving other forms of medical radiation113, nor for
occupational workers or the public. Recognizing this limitation, in 2014 the International Atomic
Energy Agency (IAEA) released a call for action to “strengthen the radiation protection of
patients and health workers overall,” in which their first recommended actions were to enhance
the implementation of justification and optimization in planned radiotherapy exposures114. Our
literature search revealed the lack of an algorithmic method to justify and/or optimize planned
radiation exposures that is comprehensive and generally applicable.
The purpose of this study was to develop a new, comprehensive conceptual framework and the
corresponding quantitative methods to aggregate the benefits and detriments of a planned
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radiation exposure to individuals, groups, and populations. Specifically, we developed a
comprehensive figure of merit () that takes into account arbitrary host- and exposure-related

factors, endpoints, and time points. We then applied this  to three illustrative examples of
planned exposures: emergency response, diagnostic imaging, and cancer radiation therapy, to
evaluate its utility in diverse settings.
4.2. Methods
4.2.1. Comprehensive Figure of Merit

Our proposed  builds on concepts in the `y formalism, with the introduction of three

important new capabilities. First, we generalized it for application to individuals, groups, and
populations. Second, we consider arbitrary numbers and types of benefits and/or detriments of
planned exposures. Finally, we added the approach of limitation by introducing a penalty factor
in the  for exposures in excess of specified exposure limits (e.g., regulatory limits).

The  for an exposed individual of attained age, , following the planned exposure at age 
was calculated by,

,  = `z{ ,  × |1 − } , ~ ,

4.1

where ` is a penalty factor for exceeding applicable exposure limits†, and { ,  and } , 
are the figures of benefit and detriment, respectively.

Although seemingly antithetical, we modeled { ,  and } ,  using identical principles.
Namely, they were calculated using

†

Exposure limits are a mechanism to constrain algorithmic optimization from converging on a solution that
concentrates risk, e.g., in one person in a group. This allows explicit consideration of the ethical principal of justice
in the optimization.
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{ ,  = ∑q `{, , ,  × 7{, × {, ,  × {,

4.2


} ,  = ∑(q
`},( , ,  × 7},( × },( ,  × },( ,

4.3



and


where Table 4.1 describes each term and its allowed domain. Figure 4.1a plots a selection of
representative examples of the relationship between the probability of an effect (`) and the dose
equivalent (). Figure 4.1b shows representative examples of the relationship between ` and
time since exposure (w =  − ), for early- and late-occurring detrimental effects.

The penalty factor, `, in Eq. 4.1 was calculated by,
L

L,
` =  =
>

q



4.4

where L is the number of exposure limits applicable to the exposed individual, L, is the value
of the th exposure limit, and  is the corresponding planned exposure, specified in the same

units. It should be noted that the number of exposure limits applied and their magnitudes are
selected according to traditional categories, (e.g., fetus, minor, adult, occupational worker,
patient, maximally exposed occupational worker, average member of the public, etc.). The

exponent  governs the rate of change in magnitude of the penalty factor as a function of dose
equivalent,  , or
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Table 4.1. Terms involved in calculating the figures of benefit and detriment using Eqs. 4.2 and
4.3. Details include the symbol, description, and allowed domain for each term. All parameters
are unitless.
Term
Description
Allowed Domain
Benefit
Detriment
Number of possible benefits () or detriments
0≤≤∞

(
(o)
0 ≤ `, ,  ≤ 1
`{, , ,  `},( , ,  Probability of a radiogenic effect as a
function of the dose equivalent, , attained
age, , and age at exposure,  (see Figure
4.1)
0≤7≤1
7{,
7},(
Maximum relative magnitude of effect
0 ≤ ,  ≤ 1
{, , 
},( ,  Factor for other mitigating circumstances
(e.g., competing causes of mortality) as a
function of attained age, , and age at
exposure, 
Factor for other considerations that might be
0≤≤1
{,
},(
important to the decision-making process
(e.g., personal preference, economic
gain/cost, access to follow up/intervention)

Figure 4.1. Representative examples of the differential probability of radiogenic effect, P, versus
(a) dose equivalent, H, and (b) time since exposure, t. (a) Selection of dose-response functions
for late effects including the linear-non-threshold, linear-exponential, and linear-plateau models;
and the mechanistic model of Dasu et al.115 (b) Representative examples of the relationship
between P and time since exposure, w =  − , for early- and late-occurring effects, respectively.
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 = P

0

L,

L,
 C 1

L,
for
 T 1,


for

4.5

where L, governs how rapidly the penalty increases with increasing exposure when the
exposure limit, L, , is exceeded. L, is a user-selected parameter of magnitude ≥ 1. Thus,
penalties are only applied if an exposure exceeds a corresponding limit. Figure 4.2 plots some
representative examples of penalty factor curves.

Figure 4.2. Representative examples of the Penalty Factor (PF). (a) PF versus planned dose
equivalent (H) for a single exposure limit (L, ) at a selection of possible exponent magnitudes
(L, ). (b) Plot of  from Eq. 4.5 versus H for the same exposure limit (L, ) and exponent
magnitudes (L, ) as in panel (a).
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 , from the age at exposure, , to attained age, , was
The cumulative figure of merit, 
calculated by,
 =  , d ≈ ∑: : ,  ∆: ,



4.6

where ∆: is the time differential of : , . In this work, we calculated cumulative lifetime
figures of merit on the assumption that the maximum attained age, , is 100 years.‡ It should also
 can be calculated directly using
be noted that 
 = `z
{ × |1 − 


} ~ ,

4.7

{ = ∑


q `{,  × 7{, × {,

4.8

 


} = ∑(q `},(  × 7},( × },(

4.9

{ and 

where 
} are the cumulative lifetime projections of the figures of benefit and detriment,
respectively, calculated by,

and,


where `
{,  and `},(  are the cumulative lifetime projections of the probabilities of benefit
and detriment, respectively. These could be calculated, for example, using models like that of
ICRP Report 60116. Note that in accumulated figures of benefit and detriment, the temporal
factors {, and },( do not explicitly appear in Eqs. 4.8 and 4.9 as they are already implicitly

included in the values of `
{,  and `},( .

‡

While we chose to calculate cumulative lifetime figures of merit, one could also calculate for arbitrary values of
attained age  C  (the age at exposure).
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The preceding methods may also be applied to groups or populations. For example, say {
individuals experience benefit and } individuals incur detriment. Then, for this application we
have a figure of merit for a population of  individuals calculated by,




 ,  =  {,: ,  ×  1 − }, , 
:q

4.10

q

where {,: w and }, w are the figures of benefit and detriment to the  th and th individuals,
respectively. {,: w and }, w are defined as in Eqs. 4.2 and 4.3. Note that this approach allows
full and explicit accounting of the benefit and detriment to each individual in the group or
population, whether they incur only risk, only benefit, or both, as the scenario may require.
Thus far, the formalism was evaluated for each individual, separately considering all of the
various benefits, detriments, and exposure penalties unique to each individual exposed
independently (Eq. 4.1) or as a member of a group or population (Eq. 4.10). In some cases, it is
convenient or necessary to forego calculations for each individual and to directly estimate
, can be
population-averaged results. The direct population-averaged , denoted by 
calculated using

 z{ 
,  = `
{ ,  × } |1 − 
} , ~,

4.11





{ ,  = ∑q 
`{, , ,  × 
7{, × 
{, ,  × {, ,

4.12

 = ∑ 

 


{
q `{,  × 7{, × {, ,

4.13

 



} ,  = ∑(q
`},( , ,  × 
7},( × 
},( ,  × },( ,

4.14
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 = ∑ `

 



}
(q },(  × 7},( × },( ,


¡L,
L
 = ∏
`
q 8  ;
¡

,

4.15

4.16

and
 
 = 

, d ≈ ∑ 

` ¢B 
B × D 1 − 
D ¤ =  
 ,  ∆ ,

4.17

where all parameters are the population-averaged magnitudes for those previously defined for an
individual (see Table 4.1).
4.2.2. Illustrative Example Calculations
To evaluate the utility of this  for justifying and optimizing planned radiation exposures, we
explored its application to inform decision making in three example scenarios: emergency
response, diagnostic radiology, and cancer radiotherapy.
4.2.2.1 Emergency Response
In this hypothetical example, we optimized shift assignments for radiation workers during an
emergency-response operation. The workers’ goal is to minimize the imminent release of a
radioactive plume. A nearby town contains 78,000 inhabitants, each of whom would receive a
uniform whole-body, hard gamma-ray exposure rate (1 Sv/h) as the plume passes overhead
(assumed exposure duration of 1 hour). The operation comprises two separate tasks. Task A
involves isolating a cracked pipe to minimize the release of radioactive gas. Task B involves
repairing damaged shielding surrounding a second pipe. Tasks A and B are separate and distinct
(see Table 4.2), and both are necessary to minimize the plume (i.e., no task can be neglected over
the course of the operation). Additionally, there are 10 available workers, where each worker is
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available for one 8-hour shift. With the workers and time available, it is not possible to entirely
prevent a release (i.e., the work required ≫ capacity to complete it) and therefore, the inhabitants
of the town will incur some exposure.
Table 4.2. Details of exposure rates to radiation workers and inhabitants in the illustrative
example calculation for emergency response. Details include the population-averaged exposure
¦§ worker, to workers assigned to task A or B and the reduction in the projected exposure rate
rate, 
¦§ public , per person-hour (PH), , of effort applied to each task.
to the public, 
Task
A
B

¦§ worker

(mSv/h)
3.0
0.7

¦§ public




(mSv/h/PH)
−10.2
−6.1

Planning these exposures requires two decisions. First, we must decide how many of the 10
available workers to assign to tasks A and B. Next, we must decide how long each worker will
perform tasks A and B. To reach wise decisions, we must justify exposures to each individual. In
addition, we must optimize exposures to all individuals, groups, and populations. We must also
limit exposures to responders and inhabitants in order to comply with regulatory limits.
Justification, optimization, and limitation must respect the ethical principles of justice (e.g., no
individual may be sacrificed for the greater good) and autonomy (e.g., each worker must be
informed of risks and be allowed to make autonomous decisions regarding his or her exposure).
We applied our comprehensive figure of merit to this case in order to objectively justify and
optimize exposures associated with the decisions regarding worker assignments. Specifically, we

 , see Eq.

used the cumulative lifetime projection of the population-averaged figure of merit (

4.17) to guide an algorithmic optimization of the assignment of the number of workers to tasks A
and B and the time duration of each worker’s assignment(s). We applied the principle of

 , see Eq. 4.16) based on the recommendations of the
limitation by way of the penalty factor (`
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ICRP, i.e., L, was 20 mSv/y averaged over 5 years and not to exceed 50 mSv in any one year

for occupational exposures and 1 mSv/y for public exposures100.

We calculated the population-averaged figure of merit in this example corresponding to
cumulative lifetime projections of the benefits and detriments using Eqs. 4.13 and 4.15 (i.e., the


temporal factors, 
} ,  and { , , in Eqs. 4.12 and 4.14 were implicitly included in the
cumulative probabilities of benefit and detriment). We calculated the cumulative figure of
 , using Eq. 4.13 in consideration of a single

benefit for the example in emergency response, 
{,©ª
benefit, avoidance of the risk of harmful effect from exposure to the radioactive plume. The risk
of harmful effect considered was the lifetime incidence of radiogenic cancer from uniform,
external, whole-body gamma-ray exposure. Thus, we calculated the cumulative populationaveraged probability of benefit as,

  = 

¦§avoided × 
`
¬ ,
{

4.18

¦§avoided was the avoided exposure rate to the inhabitants due to the emergency-response
where 

operation and ¬ was the population-averaged lifetime risk coefficient for fatal radiogenic

cancer induction per dose equivalent, taken as 5%/Sv100.§ More specifically,
¦§avoided = 
¦§A × 
¦§B × 

∆w + 
∆w

4.19

where 
∆w was the projected duration of the exposure of inhabitants to the plume, assumed to be

¦§A and 
¦§B were calculated by,
1 hour, and 
§

Other, more detailed models may be used to calculate the probability of beneficial and/or detrimental effects, such
as those published in the Biological Effects of Ionizing Radiation (BEIR VII) report. For simplicity, we used the
model from the International Commission on Radiological Protection (ICRP) report number 60.
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¦
¦§A = 8¡public ; × TA ,


§

4.20

A

and,
¦
¦§B = 8¡public ; × TB ,

§

where 8

¦§public
¡


; and 8
A

¦§public
¡




4.21

B

; were the decrease in the population-averaged exposure rates to the
B

public per person-hour of effort applied to complete tasks A and B, respectively (Table 4.2), and

TA and TB were the total number of person-hours spent by exposed workers on tasks A and B,

respectively. It is necessary to explicitly include exposure durations (i.e., 
∆w , TA , and TB ) in the

equations above in order to allow algorithmic optimization and justification of exposures.
We calculated the cumulative figure of detriment (Eq. 4.15) in consideration of two detriments:
radiogenic cancer and acute radiation syndrome (ARS). We calculated the population-averaged
probability of second-cancer induction for the th exposed worker as


  = ¢

¦§worker  × wA, + 
¦§worker  × t B, ¤ × 
`
¬
},q,®
A

B

4.22

¦§worker  and 
¦§worker  were the exposure rates to the workers while performing tasks
where 
A

B

A and B, respectively (see Table 4.2), wA, and wB, were the duration of time the th worker was


assigned to tasks A and B, respectively, and ¬ was the same as in Eq. 4.18. We calculated the
cumulative population-averaged probability of ARS for the th worker, or 
`
},,® , using an
empirical sigmoidal function developed in this work based on the findings of Donnelly et al.117
(see Figure 4.3).
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Figure 4.3. Empirical model for the probability of acute radiation syndrome, 
`
ARS . `ARS versus
dose equivalent, H, which was used to quantify the population-averaged probability of the
detriment of acute radiation syndrome for the th worker, 
`
},,® . The empirical model was
developed in this work based on the findings of Donnelly et al.117
For simplicity, we considered all effects to be fatal (i.e., the benefit was to avoid a fatal cancer
and the detriments were fatal cancer and fatal acute radiation syndrome). Thus, for simplicity and
clarity in this example, we assigned the maximum value of 1 to the relative magnitudes of all
beneficial and detrimental effects (i.e., 
7{,1 in Eq. 4.13, 
7},1 , and 
7},2 in Eq. 4.15). Table 4.3 lists
 for this hypothetical scenario.

the parameters involved in calculating 
In order to decide the number of workers and assigned times, we utilized a commercially
available optimization toolbox (MATLAB version R2016a, The MathWorks Inc., Natick,
Massachusetts, United States) to perform an iterative optimization of the shift assignments. We
discretized the duration of assignments to 30-minute intervals. Thus, each worker was assigned
to either task A or task B for each 30-minute interval of their 8-hour shift. This optimization
searched through the 10-dimensional parameter space comprising 137 billion possible shift-
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 magnitude
assignment combinations |¯wA, °∀ and where w{, = 8 h − w±, ~. The largest 

indicated the optimal shift-assignment combination, i.e., the exposures were justified, optimized,
and limited.
Table 4.3. List of parameters and equations for calculating the cumulative lifetime projection of
 ) for the illustrative example in emergency

the population-averaged figure of merit (
response. Data include the term, description, and the corresponding value, equation, or figure.
Value, Equation,
Term
Description
or Figure
Population of benefitted inhabitants
78,000
B
Number of radiation workers experiencing the detriment
10
D
Exposure limit applied to radiation workers
20 mSv/yr100
L,1
Exposure limit applied to the public (i.e., inhabitants in the
1 mSv/yr100
L,2
nearby town)
Exponent driving the rate of change of the penalty factor for
10
L,1
exceeding L,1 (see Eq. 4.5)
Exponent driving the rate of change of the penalty factor for
10
L,2
exceeding L,2 (see Eq. 4.5)

Penalty factor for exceeding applicable exposure limits (i.e.,
Eq. 4.16
`
L,1 and L,2 )

Cumulative probability of avoided risk of harmful effect (i.e.,
Eq. 4.18

`
{
fatal radiogenic cancer incidence) attributed to the operation

Magnitude of the harmful effect for which risk is avoided by
1
7{
the operation (i.e., fatal cancer)

Factor for other considerations related to the benefit
1
{

Cumulative
population-averaged
figure
of
benefit
for
the
Eq.
4.13

{,©ª
example scenario in emergency response

Cumulative
probability of cancer incidence resulting from
Eq. 4.22

`},q
exposures incurred while completing the shift assignment

Magnitude of the incident cancer attributed to the shift
1
7},q
assignment (i.e., potentially fatal)

Factor for other considerations related to the detriment of
1

},q
cancer incidence
Cumulative probability of acute radiation syndrome resulting
See Figure 4.3

`
},
from exposures incurred while completing the shift assignment

Magnitude of acute radiation syndrome attributed to the shift
1
7},
assignment (i.e., potentially fatal)

Factor for other considerations related to the detriment of acute
1

},
radiation syndrome
Population-averaged figure of detriment for the illustrative
Eq. 4.15


},©ª
example in emergency response
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4.2.2.2 Diagnostic Radiology
An example application of the figure-of-merit framework to the field of diagnostic radiology is
as a decision aid in justifying a new screening procedure. The goal of this hypothetical example
was to identify the most appropriate breast-cancer screening procedure for universal screening of
women between the ages of 50 and 74118. We considered two alternative methods for this
example: the current standard of care, namely, digital mammography alone (DM), versus a
proposed new standard of care, digital breast tomosynthesis (DBT) in conjunction with digital
mammography, denoted by (DBT+DM).
This decision requires the justification of exposures to each individual in a large population of
apparently healthy women. Justification considered the ethical principles of autonomy (i.e.,
patients must be informed of the benefits and risks and their personal decision respected) as well
as the principles of beneficence and non-maleficence (i.e., the benefits should outweigh the
detriments). These diagnostic radiology procedures comprise small medical exposures, and
therefore the principle of limitation was not applied here.
We used our comprehensive framework to objectively justify the selection of the most
appropriate procedure. Specifically, we calculated the cumulative lifetime projection of the
 , see Eq. 4.17) for each procedure in order quantify the

population-averaged figure of merit (
 magnitudes. We calculated the
net benefit to each patient and then compared the resulting 

 in this example for lifetime projections of the benefits and detriments using Eqs. 4.13 and


4.15 (i.e., the temporal factors, 
} w and 
{ w, in Eqs. 4.12 and 4.14 were implicitly included
in the cumulative probability calculations). We calculated the cumulative population-averaged
figure of benefit for the example in diagnostic radiology, 

{,}ª , using Eq. 4.13 in consideration
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of a single benefit, the correct detection of a potentially fatal (but curable in 50% of cases if
treated) breast cancer. We estimated the cumulative population-averaged probability of this
, with the population-averaged positive predictive value (``²
 )119 of each screening
benefit, 
`
B
procedure. The 
``² quantifies the probability that subjects with a positive test result actually
have the disease. We represented the magnitude of this benefit, 
S{ , as the relative magnitude of
the harmful effect that is avoided by a successful screening procedure (i.e., the lethality factor of
breast cancer, taken from ICRP Report 60100).**
We calculated the cumulative population-averaged figure of detriment for this example, 

},}ª ,
using Eq. 4.14 in consideration of a single detriment, radiogenic breast-cancer induction. The
 , was the probability of radiogenic breast-cancer
cumulative probability of this detriment, 
`
D
induction resulting from the use of each procedure as a universal screening tool120 and the
S} , was the lethality of breast cancer100. Table 4.4 lists the
relative magnitude of this detriment, 
 for DM and DBT+DM. We identified the
magnitudes of the factors involved in calculating 

 as the most appropriate breast-cancer screening procedure for
procedure with the higher 

universal screening.
4.2.2.3 Cancer Radiotherapy
In a final example, we applied the new framework to aid decision making in cancer radiotherapy.
The goal of this hypothetical example was to decide between two alternative personalized
treatment options (i.e., planned exposures) available to a 60-year-old man with prostate cancer:
conventional photon radiotherapy (CRT) and watchful waiting (WW). Such a decision entails,
among many other factors, the justification of any exposure to the patient. Cancer radiotherapy

**

These were used for simplicity. More accurate data are available and could be used in this framework.
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Table 4.4. List of parameters and equations for calculating the cumulative lifetime projection of
 ) for the illustrative example in diagnostic

the population-averaged figure of merit (
radiology. Data include the term, description, and the corresponding value or equation for digital
mammography alone (DM) and digital breast tomosynthesis in conjunction with digital
mammography (DBT+DM).
Value/Equation
Term
Description
DM
DBT+DM
Number of people experiencing the benefit of the
1
1
B
planned exposure (i.e., the patient)
Number of people experiencing the detriment of the
1
1
D
planned exposure (i.e., the patient)
L, Applicable exposure limit
Exponent driving the rate of change of the penalty
0 (Eq. 4.5)
0 (Eq. 4.5)
L
factor for exceeding L
 Penalty factor for exceeding applicable exposure
1 (Eq. 4.16)
1 (Eq. 4.16)
`
limit (i.e., L )

Cumulative
probability of correctly detecting breast
4.1%119
6.4%119

`{
cancer (i.e., the positive predictive value)

Magnitude of the benefit (i.e., harmful effect avoided
0.50100
0.50100
7{
by successful screening, lethality of breast cancer)

Factor for other considerations related to the benefit
1
1
{

Eq. 4.13
Eq. 4.13

{,}ª Cumulative population-averaged figure of benefit for
the illustrative example in diagnostic radiology

Cumulative probability of radiogenic breast-cancer
25/100,000120 75/100,000120

`
}
incidence resulting from screening exposure

Magnitude of the detriment attributed to the
0.5100
0.5100
7}
screening procedure (i.e., lethality of breast cancer)

Factor for other considerations related to the
1
1
}
detriment of radiogenic cancer incidence

Eq. 4.15
Eq. 4.15

},}ª Cumulative population-averaged figure of detriment
for the illustrative example in diagnostic radiology
comprises a medical exposure, for which the ICRP recommends no exposure limits. As in the
previous example, we did not apply exposure limits and we did respect the ethical principles of
autonomy, beneficence, and non-maleficence.
We employed our comprehensive figure of merit to provide an algorithmic and personalized
approach to justify the treatment plan selected. Specifically, we compared the balance between
the patient-specific benefits and detriments (i.e., beneficence and non-maleficence) for each

treatment option by calculating the population-averaged figure of merit (,
) for CRT
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and WW in each year after treatment. We calculated the population-averaged figure of benefit
for each treatment option (i.e., CRT and WW) using Eq. 4.12 in consideration of a single benefit,
control of the tumor. We estimated the population-averaged probability of benefit from CRT,


`
B,CRT , , with the tumor control probability, U`, . For this example, we assumed

U`,
 was 95% and constant in time following treatment. We considered the probability of
benefit from watchful waiting, 
`B,WW , , to be the probability of survival, calculated by,

T
`B,WW ,  = 1 − ´

4.23

T was the lethality factor of prostate cancer, taken from ICRP Report 60100. In this case, 
where ´

can be thought of as the age at diagnosis and we assumed `
B,WW ,  was constant in time after

treatment. Figure 4.4 plots `
{,ªµ ,  for an illustrative selection of treatment outcomes for a
60-year-old cancer patient.
In this example, we assumed that the tumor in the prostate was potentially fatal, and thus the
benefit was avoiding a potential lethality. We accordingly assigned the maximum value of 1 to

S{ . We represented the temporal factor, 
the magnitude of the benefit, 
B , , in Eq. 4.12 as the
probability of surviving to attained age a = 100 years conditional on survival to the age of

¶
exposure, e = 60 years. This corresponds to the factor ¶ from the BEIR VII report121. We
calculated this factor from data contained in the life tables tabulated by the U.S. Department of
Health and Human Services122-125. Figure 4.5 demonstrates how this factor might differ for
different populations124, 125. In essence, the temporal factor discounts the risk of effect (in this
case, the detriment of risk of radiogenic cancer induction) because of competing causes of death
(e.g., heart failure) that may occur before a radiogenic cancer develops.
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Figure 4.4. Probability of benefit for an illustrative selection of treatment outcomes for a 60
year-old man with prostate cancer. Probability of benefit, `
B,RT , , versus attained age, , for
outcomes of tumor cure (i.e., complete response after time at exposure, a=e), tumor recurrence
(i.e., complete response followed by recurrence 20 years post-exposure), watchful waiting (i.e.,
constant probability of survival after time of diagnosis, a=e), and palliation (i.e., short-term,
partial response).

Figure 4.5. Representative examples of the temporal factor for different populations. Temporal

¶
factor, ¶, versus attained age, , calculated from birth to age 100 based on the average survival
in the United States in years 1900125, 1950125, and 2014124.

We calculated the population-averaged figure of detriment for this example, 
},ªµ , , using
Eq. 4.14 in consideration of one detrimental effect, radiogenic cancer of the bladder. We
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quantified the probability of this detriment for CRT, `
D,CRT , , with the excess absolute risk
(EAR) of radiogenic bladder-cancer incidence for a 60-year-old male using the BEIR VII
methodology121 for an average bladder dose of 70 Gy. We considered this a conservative
estimate of dose to the bladder from photon CRT based on a random sample of 10 prostatecancer patients previously treated at our clinic (Mary Bird Perkins Cancer Center, Baton Rouge,

LA). The bladder dose for WW was 0 Gy and thus `
D,WW ,  was 0. We represented the
relative magnitude of radiogenic cancer of the bladder, 
S} , as the lethality of bladder cancer100

¶

and calculated the temporal factor for the detriment, 
D , , with ¶ (see above). Table 4.5
lists the parameters and equations needed to calculate the population-averaged figure of merit
 , see Eq.


(,
). From this, we calculated the cumulative projected figure of merit (
 as the optimal

4.17) and selected the personalized treatment option with the higher 
treatment for this patient.
4.3. Results
4.3.1. Emergency Response
Figure 4.6 plots the cumulative lifetime population-averaged figures of benefit, 

{,©ª , and
th
detriment, 

},©ª , associated with tasks A and B versus the amount of time the  worker is

assigned to task A, t A, . These data reveal the opposite monotonic progressions of the benefit and
detriment associated with the tasks. The magnitude of 

{,©ª for task A crosses that for task B at
 ’s for tasks A and B cross at t = 1.5 hours. From inspection of

t A, = 3 hours while the 
},©ª
A,
these plots alone, the optimal shift assignments are not apparent. Naively, considering only
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Table 4.5. List of parameters and equations for calculating the population-averaged figure of

merit (,
) for the illustrative example in cancer radiotherapy. Data include the term,
description, and the corresponding value or equation for the two candidate treatment options:
conventional photon radiotherapy (CRT) and watchful waiting (WW).
Value/Equation
CRT
WW
Term
Description
Number of people experiencing the benefit of the
1
1
B
planned exposure (i.e., the patient)
Number of people experiencing the detriment of
1
1
D
the planned exposure (i.e., the patient)
Applicable exposure limit
L,
Exponent driving the rate of change of the
0 (Eq. 4.5)
0 (Eq. 4.5)
L
penalty factor for exceeding L

Penalty factor for exceeding applicable exposure
1 (Eq. 4.16)
1 (Eq. 4.16)
`
limit (i.e., L )

Probability of therapeutic benefit (i.e., tumor
0.95∀ ≤  ≤
0.45∀ ≤  ≤
`{ , 
cure)
100 (this work) 100 (Eq. 4.23)100

Magnitude of the benefit (i.e., harmful effect
1
1
7{
avoided by successful cancer radiotherapy,
potentially lethal prostate cancer)



¶
¶
Factor for other circumstances mitigating the
{ , 
∀
≤

≤
∀ ≤  ≤
¶]·
¶]·
benefit of the planned exposure (e.g., competing
100 121
100 121
causes of mortality) as a function of time, w, since
the planned exposure

Factor for other considerations related to the
1
1
{
benefit

Eq. 4.12
Eq. 4.12
{,ªµ ,  Population-averaged figure of benefit for the
illustrative example in cancer radiotherapy

Probability
of radiogenic bladder-cancer
EAR121
0
`} , 
incidence resulting from radiotherapy exposure

Magnitude of the detriment attributed to the
0.5100
0.5100
7}
radiotherapy exposure (i.e., lethality of bladder
cancer)



¶
¶
Factor for other circumstances mitigating the
} , 
w =  121
w =  121
¶]·
¶]·
detriment of radiogenic cancer incidence (e.g.,
competing causes of mortality) as a function of
time, w, since the planned exposure

Factor
for other considerations related to the
1
1
}
detriment of radiogenic cancer incidence

Eq. 4.14
Eq. 4.14
},ªµ ,  Population-averaged figure of detriment for the
illustrative example in cancer radiotherapy
benefits, one would seek to select a shift assignment that maximizes the benefits from both tasks
and might subjectively choose to assign all 10 workers to t A, = 3 h. Considering only the
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detriments, on the other hand, one would seek to keep the detriments from both tasks low and
thus might believe t A, = 1.5 h is desirable. Therefore, considering the benefit and detriment
together, we might expect a subjective analysis to arrive at a shift assignment of 1.5 h ≤ t A, ≤
3 h.

Figure 4.6. Figures of benefit to inhabitants and detriment to workers for the illustrative example
 , and (b) detriment, 

in emergency response. Figures of (a) benefit, 

{,©ª
},©ª , attributed to effort
th
spent on tasks A and B versus the amount of time the  worker is assigned to Task A, t A, .
Points indicate the possible 30-minute shift intervals.
 , Eq.

Figure 4.7 plots the lifetime projection of the population-averaged figure of merit (
4.17) for an illustrative subset of possible shift-assignment combinations (i.e., those for which all
 takes benefits,

10 workers received identical relative shift assignments, t A,q = t A, = t A,q·). 
detriments, and applicable exposure limits into account and allows for a comprehensive
evaluation of this planned exposure. In Figure 4.7, the optimal shift assignment is readily
 magnitude, and is distinctly different
apparent (t A, = 6 h), as indicated by the maximum 

from our subjective conclusion based on Figure 4.6. Indeed, our iterative optimization converged
on assigning all 10 workers to the same relative shift assignments (i.e., each of the 10 workers
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assigned to 6 hours on task A and 2 hours on task B). This resulted in a planned 19.4
mSv/worker over the course of the 8-hour shift. This result reflects the principle of limitation by
keeping each worker below applicable limits (i.e., an average of 20 mSv/y over 5 y and not to
exceed 50 mSv in any one year100). Furthermore, the optimized shift assignments are just in that
they evenly distribute the exposures across the group rather than sacrificing any individual for
the greater good. This combination of shift assignments reduced the exposure to the inhabitants
by 73.4% to 0.27 Sv over the course of the entire one-hour exposure.

Figure 4.7. Population-averaged figure of merit for the illustrative example in emergency
 , versus the amount of time worker  is

response. Population-averaged figure of merit, 
assigned to Task A, t A, for a representative set of shift-assignment combinations considered by
the iterative optimization algorithm. Points indicate the possible 30-minute shift intervals. The
vertical dashed line indicates the optimal shift assignment.
4.3.2. Diagnostic Radiology
 ) for digital breast tomosynthesis in

The cumulative population-averaged figure of benefit (
{
conjunction with digital mammography (DBT+DM) in this hypothetical scenario was a factor of
1.6 larger than that for digital mammography alone (DM). The cumulative population-averaged
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 ) for DBT+DM, however, was three times that for DM. As with the

figure of detriment (
D
example in emergency response, these data, which represent the benefit and detriment separately,
do not reveal the optimal selection. The lifetime projection of the population-averaged figure of
 ), we shall see, overcame this limitation by aggregating the benefit and detriment.

merit (
 for DBT+DM and DM were 0.032 and 0.020, respectively. Put another way, the 



The 
for DBT+DM was a factor of 1.6 larger than that for DM. This suggests that the added benefit of
 )) outweighs the additional detriment (i.e.,
DBT (i.e., the increased positive predictive value (``²
the increased risk of radiogenic breast-cancer incidence) for individuals in the population. More
specifically, the use of DBT+DM as a universal screening tool is projected to induce an
additional 50 radiogenic breast cancers while accurately diagnosing an additional 2,300 breast
cancers in a population of 100,000 women. These results demonstrate the clear consideration of
the principles of beneficence and non-maleficence in an algorithmic and objective framework for
justifying the use of DBT+DM as a universal screening method.
4.3.3. Cancer Radiotherapy
Figure 4.8 plots the population-averaged figures of benefit, 
B,RT , , and detriment,

D,RT , , for the hypothetical example of the lifespan of a 60-year-old man with prostate
cancer following two different treatment approaches: conventional photon radiotherapy (CRT)
and watchful waiting (WW). These data show that while the benefit for CRT is larger than that
for WW, so too is the detriment. Furthermore, while the benefit for both CRT and WW peak in
the year of diagnosis/treatment (a = 60 y) and monotonically decrease thereafter, the detriment
from CRT peaks 25 years later (a = 85 y), obfuscating the optimal treatment choice for this
patient. It should be noted that the decrease in the figures of benefit for both treatment options is
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due to the increasing importance of other sources of mortality later in life. This manifests by the


magnitudes of the temporal factors, 
{ ,  and } ,  (see Eqs. 4.12 and 4.14), which
sharply decrease towards the end of life.

Figure 4.8. Figures of benefit and detriment for the illustrative example scenario in cancer
B,RT , , and (b) detriment, 
D,RT , , versus attained
radiotherapy. Figures of (a) benefit,
age, a, for two alternative hypothetical treatment approaches for a 60-year-old man with prostate
cancer: conventional photon radiotherapy (CRT) and watchful waiting (WW).
Figure 4.9 shows the population-averaged figure of merit, 
, , over the life of a 60-yearold man with prostate cancer following conventional photon therapy (CRT) compared to that for
watchful waiting (WW). This figure shows that 
,  was 0 until the age of
diagnosis/treatment (a = 60 y) for both treatment plans. After this time, the largest 
, 
occurred in the year of diagnosis/treatment. The same monotonic decrease that was seen in the
figures of benefit is evidenced in the 
, ’s for both CRT and WW, mainly due to
competing causes of death. Still, CRT resulted in a larger 
, , even at an attained age of
85 years, where its associated detriment was at a maximum. The figure of merit accumulated
 ) for CRT was a factor of two larger than that for watchful

over the patient’s lifetime (
waiting (23.51 versus 11.32, respectfully), thereby justifying the CRT treatment and its
associated risk and ensuring a thorough consideration of the ethical principles of beneficence and
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 for CRT represents adding
non-maleficence for this patient. We estimate that the increased 

27 healthy years of life to the patient’s life expectancy compared to that for WW.

Figure 4.9. Population-averaged figures of merit for the illustrative examples in cancer

radiotherapy. Population-averaged figure of merit,,
, versus attained age, a, for two
alternative treatment approaches for a 60-year-old man with prostate cancer: conventional
photon radiotherapy (CRT) and watchful waiting (WW).
4.4. Discussion
In this study, we developed a new, comprehensive conceptual framework and corresponding
quantitative methods to aggregate the benefits and detriments of planned radiation exposures to
individuals, groups, and populations. We did this by way of a comprehensive figure of merit
() that takes the major host- and exposure-related parameters into account. We then
demonstrated the utility of this new framework in three illustrative planned-radiation-exposure
examples: emergency response, diagnostic imaging, and cancer radiation therapy. The major
finding of this work is that, for the first time, it is possible to quantitatively combine the various
benefits and detriments of any planned radiation exposure to an individual or society in a way
that enables justification and/or optimization of that exposure in an objective and automated
manner.
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This new framework has several important implications. First, the generalized, comprehensive
nature of the algorithm developed here enables optimization and justification of arbitrarily
complex exposure situations. This has the potential to open new avenues of inquiry in a variety
of planned-exposure settings. For example, the algorithm could be used to facilitate the
introduction of new radiation technologies (e.g., medical procedures) by providing a framework
to aid in justifying changes to standard practices, or to improve health outcomes for patients by
guiding patient-specific, outcome-based decisions. There are also many industrial sectors that
utilize radiation, including sterilization (e.g., to disinfect food126 and medical equipment127),
environmental safety (e.g., to remove toxic pollutants from the air128), fashion (e.g., to treat
clothing129), and agriculture (e.g., to improve food production130) to which this framework could
be applied. Another important implication of this new framework is that it provides a means to
more fully respect the ethical principle of autonomy. Respecting an individual’s autonomy
requires clear and accessible communication of all of the possible outcomes (i.e., beneficial and
detrimental) of a planned exposure and giving them the freedom to make their own decisions on
the basis of informed deliberation1. An important requisite step to this is the quantification of all
possible effects and their relative magnitudes. The framework developed in this work can in
principle automatically provide the complete information necessary for empowering individuals
to exercise autonomy.
The major strength of the framework developed in this work is that the methods are generally
applicable. The figure of merit () can consider arbitrary numbers of benefits and detriments
of varying magnitudes for an individual, group, or population. Thus, the  is directly related
to the overall projected health outcome of the exposed individual(s), including benefit,
morbidity, and mortality. Finally, the framework is consistent with existing radiation-protection
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practices. These characteristics greatly increase the ’s scope of applicability, as
demonstrated by the example calculations presented here.
This study has several limitations. First, the accuracy of the  is limited by the accuracy of
the absolute dose-response models used to calculate the benefits and detriments. We did not
consider this a significant limitation for two reasons. First, our methods involved comparing the
relative  magnitudes between two or more options (e.g., different shift-assignment
combinations, DM vs DBT+DM, and CRT vs WW) rather than drawing any conclusions from
the absolute  magnitudes. When used in this way, the covariance decreases the overall
uncertainty, rendering the results less sensitive to uncertainties in the dose-response models.
Second, the  was designed in such a way that new, more accurate models can easily be
integrated into the framework as they become available. This is a focus of radiation-biology and
radiation-epidemiology research18, 131. Another limitation of this study is that we did not
explicitly take economic considerations (e.g., costs or savings) into account in our examples.
Cost-effectiveness of a planned exposure is an important consideration in many settings.
Although we did not consider economic effects in the examples in this study, the formalism

includes a provision for this and other factors (i.e., in {, and },( in Eqs. 4.2 and 4.3 and 
{,

and 
},( in Eqs. 4.12 through 4.15). There is strong interest to include such considerations; the
European Society for Radiotherapy and Oncology (ESTRO) recently launched a Health
Economics in Radiation Oncology (HERO) project, which aims to develop a database and model
for health-economic evaluations in radiotherapy132. Efforts like the HERO project will greatly
facilitate the consideration of economic burden and gain in the proposed framework.
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4.5. Conclusion
We developed a comprehensive figure of merit, , for guiding decisions on planned radiation
exposures and evaluated its utility in three illustrative examples. This  fills a chronic gap in
the application of radiation-protection theory, namely, the lack of a generally applicable
framework and set of corresponding quantitative methods to algorithmically justify and optimize
any planned-exposure scenario. This new framework enables the comprehensive and algorithmic
risk-benefit analysis of planned radiation exposures to individuals, groups, and populations and
translates the subjective guiding principle of optimization, or “as low as reasonably achievable”
(i.e., ALARA), into a more rigorous foundation. Our application of the proposed framework to
three illustrative example scenarios suggests that it could find use in a wide range of plannedexposure settings, including medicine and industry. The  developed in this work could
provide a more objective approach to complex, subjective pillars of radiation protection (i.e.,
justification and optimization), while maintaining coherence with existing methods, which are
largely based on the principle of limitation. This has the potential to enable the full realization of
the long-term benefit of planned radiation exposures to individuals and society.
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Chapter 5. Generalized Approach to Radiotherapy Treatment Planning by
Optimizing Health Outcome Instead of Dose: Preliminary Results for
External-Beam Prostate Radiotherapy
5.1. Introduction
Advancements in cancer care in recent decades have increased survival rates to nearly 70%
overall and 85% in children4. This increase was mainly driven by improved cures for primary
cancers. Epidemiological studies have revealed that the majority of cancer survivors suffer from
myriad health conditions, even decades after the completion of treatment7, 133-140. These health
conditions can have profound impacts on the survivor’s length and quality of life by affecting
their mortality141, cognition142, 143, employability144, fertility145, and access to survivorship
care146, to name a few. This has highlighted the fact that tumor cure is not the only hallmark of
cancer survivorship147. In fact, the full beneficial potential of any medical intervention can only
be realized by additionally minimizing the long- and short-term side effects in healthy tissues18.
This has led to a need for innovative approaches to the planning of cancer care that consider
normal-tissue effects to provide improved outcomes in addition to tumor cure18, 147.
Current approaches in radiotherapy do attempt to prospectively limit side effects by constraining
the dose received by normal tissues to be less than empirically determined tolerance dose values.
More specifically, constrained iterative optimization of dose distributions is used as a surrogate
for optimization of the patient’s health outcome. These dosimetric constraints, however, rarely
serve as reliable predictors of outcome due to interpatient variation in radiation sensitivity19.
Research on direct optimization of health outcome is at an early stage. Researchers have
attempted to improve outcomes directly by varying treatment factors, including the treatment
modality22, 112, prescription dose25, 27, 30, 32, 148, fractionation scheme28, and beam-weight
combination29, 31. Most of these studies have focused on the short-term effects of radiotherapy
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and neglected the long-term health effects, which may seriously impact a patient’s quality and/or
length of life22-28. Only three studies optimized aspects of radiotherapy delivery based on the
long-term side effects29-31, of which two included considerations of the dose from stray radiation
sources29, 32. These stray radiation sources deliver low doses of radiation to large volumes in the
patient (i.e., the entire body) and increase the risk of late-occurring side effects74, 75. To our
knowledge, no study has yet attempted to optimize radiotherapy treatment plans in consideration
of all types of outcomes (i.e., long- and short-term side effects) associated with the total dose
(i.e., therapeutic and stray) deposited in individual patients. Thus, it is not yet known whether it
is feasible to optimize radiotherapy treatment plans based on the longitudinal (i.e., long- and
short-term) outcomes of the therapeutic and stray radiation exposures in individual patients.
The goal of this study was to develop a generally applicable method to directly optimize
projected longitudinal outcomes in consideration of arbitrary numbers and types of radiogenic
effects. To accomplish this, we developed an outcome-based objective function to replace dosebased constraints and penalties in radiotherapy treatment-plan optimization. This work
demonstrates a practical application of this objective function to optimize photon and proton
radiotherapy treatment plans in a sample of ten patients with low-risk prostate cancer.
5.2. Methods
In this study, we optimized photon and proton radiotherapy treatment plans in a sample of ten
prostate-cancer patients. We begin by describing the sample and anatomical regions of interest
(Section 5.2.1). Next we detail the treatment-planning (Section 5.2.2) and optimization (Section
5.2.3) methods, and the objective functions used to guide these optimizations (Section 5.2.3.1).
Finally, we explain how we tested for improved projected health outcomes from outcomeoptimized treatment plans compared to dose-optimized treatment plans and for the
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generalizability of the proposed methods across three influence factors: treatment factors, riskprojection factors, and host factors (Section 5.2.4).
5.2.1. Patient Selection and Regions of Interest
We randomly sampled a cohort of ten early-stage prostate-cancer patients from the population of
patients previously treated at our institution (Mary Bird Perkins Cancer Center, Baton Rouge,
LA). We included all patients with an intact prostate and a single planning target volume (PTV).
We excluded patients with artificial hip implants and patients who required a sequential boost to
a sub-volume of the primary PTV. Wall et al.149 previously described this cohort. The stages at
diagnosis ranged from T1 to T2 with no nodal or metastatic involvement and the mean PTV
volume was 73 cm3 (standard deviation: 15 cm3). The average age at diagnosis was 69.2 years
(61-75 years).
Table 5.1 lists the regions of interest (ROI’s) and the projected endpoints taken into account. The
PTV is the only ROI in which we considered a beneficial endpoint, i.e., tumor control. We
selected the remaining ROI’s, or organs at risk (OARs), based on previous studies that
demonstrated increased risks following radiotherapy exposures in these organs and tissues51, 150,
151

. For the purposes of risk projection, we included the bladder wall and rectal wall and

excluded their contents (e.g., urine, excrement, and gas) following the recommendations of the
International Commission on Radiological Protection (ICRP) Publication 110152. The femoral
head (cortical bone) ROI was also defined following the recommendations of ICRP Publication
110.
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Table 5.1. Regions of interest (ROI’s) considered in the sample of ten prostate-cancer patients.
Details include the organ, projected endpoint, type of endpoint (i.e., beneficial, B, or detrimental,
D), and the magnitudes of parameters for calculating OORT (see Eq. 5.1). These values include
the probability, `: or  w, (where TCP stands for tumor control probability, NTCP stands for
normal tissue complication probability, and EAR stands for excess absolute risk); relative
endpoint magnitude, 7: or  ; factor for competing causes of death, : or  w; and factor for other
considerations, : or  .
ROI
Endpoint
Type
`: or  w
7: or 
: or  w
: or 
153
¶
121, 124
PTV
Tumor control
B
TCP
1.00 (This
1.00
¶
work)
¶ 121, 124
Bladder
Grade ≥2 toxicity
D
NTCP154
1.00155
1.00
”

Radiogenic cancer

D

EAR29, 115, 121

0.50100

Rectum

Grade ≥2 toxicity

D

NTCP156

1.00155

”

Radiogenic cancer

D

EAR29, 115, 121

0.55100

Femoral Head
(cortical bone)
Femoral Head
(bone marrow)
Remainder

Hip fracture

D

NTCP157

0.60155

Radiogenic cancer
(leukemia)
Radiogenic cancer

D

EAR29, 121, 158

0.99100

D

EAR29, 121

0.72100

¶
¶ 121, 124
¶
¶ 121, 124
¶
¶ 121, 124
¶
¶ 121, 124
¶

¶ 121, 124
¶
¶ 121, 124
¶

1.00
1.00
1.00
1.00
1.00
1.00

5.2.2. Treatment planning
We performed treatment planning using a research treatment planning system (TPS) (CERRLSU) that was previously trained and validated for 6- and 15-MV photon therapy34 (see Chapter
3) and 100 to 250 MeV proton therapy159. We selected this research TPS because it calculated
stray and therapeutic radiation whereas commercial systems only calculate the therapeutic
radiation38-40. Specifically, the photon dose calculations included contributions from therapeutic
and stray photons. The proton dose calculations included contributions from therapeutic protons
and stray neutrons created in the treatment head following the methods of Schneider et al.160 We
combined therapeutic and stray doses from proton therapy following the methods of Eley et al.83
We weighted the absorbed dose by a generic relative biological effectiveness (RBE) of 1.1 for
protons and 1 for photons161. Following the methods of Schneider et. al.160, we directly
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calculated the radiobiological quantity of neutron equivalent dose (H) in Sv, which implicitly
includes an RBE for neutrons.
We designed treatment beams for each patient following the methods of Rechner et al.29 Namely,
we placed 16 beams of each modality (i.e., 6-MV photons, 15-MV photons, and spot-scanned
protons) at equal intervals of gantry-angle separation around each patient (i.e., every 22.5
degrees) starting at 0 degrees (see Figure 5.3). For every patient, we designed each of the 16
beams to provide full coverage of the PTV. We pre-computed the absorbed dose from each beam
alone such that each one, and any weighted combination thereof, delivered the prescribed RBEweighted absorbed dose of 76 Gy (RBE) to the clinical target volume (CTV). We exported the
pre-computed dose matrices containing therapeutic- and stray-dose contributions for each beam
angle, treatment modality, and patient from the TPS and imported them into an in-house code for
beam-weight optimization (MATLAB version R2016a, Mathworks, Natick, MA).
5.2.3. Optimization
The in-house optimization code performed an exhaustive search over all permutations of the
numbers and weights of the pre-computed beams. We selected the exhaustive search over
iterative optimization approaches to avoid solutions comprising local minima, a potential source
of methodological error in a problem of high susceptibility due to its large degree of
mathematical degeneracy162. Our permutations included all combinations of 1 to 16 beams,
where all relative beam weights were positive and summed to 1. We discretized the magnitude of
relative beam weights from 0 to 1 in increments of 0.1. We took advantage of the mirror
symmetry of the pelvis about the sagittal plane, whereby corresponding left and right beams (i.e.,
at equal angular displacement from 0 degrees) induce roughly equivalent outcome. Specifically,
we set corresponding left and right beams to equal weights (i.e., each beam in a left-right pair
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could bear relative weights ranging from 0 to 0.5 in steps of 0.05). Note that the beams at angles
of 0 and 180 degrees (i.e., anterior-posterior and posterior-anterior) did not have a corresponding
left-right partner. This procedure resulted in a total of 43,758 possible discretized beam-weight
combinations, henceforth referred to as treatment plans for brevity.
The optimization procedure calculated the composite dose from each treatment plan by
weighting and summing the pre-computed dose matrices from each of the 16 beams for each
patient and each treatment modality. Next, it calculated the magnitude of an objective function

() for each treatment plan. The plans were then ranked and sorted in ascending order of .
Finally, the plan with the smallest  was identified as the optimal treatment plan.

5.2.3.1 Objective Functions

We ranked and sorted the pre-computed treatment plans in this study by the values from two
different objective functions. One was for our proposed outcome-optimized radiotherapy
(OORT) treatment plans and the other was for dose-optimized radiotherapy (DORT) treatment
plans, which is similar to the current standard of care. We designed the outcome-based objective
function, OORT , to be simple and intuitive, yet comprehensive to take into account arbitrary

numbers of benefits and detriments of the planned treatment. Specifically, we calculated OORT

as,
¸

OORT = − |B w − D w~

5.1

x

where  is the attained age at exposure, ¹ is the attained age at the end of life (assumed here to be
at an age of 100 years), and B w and D w are the figures of benefit and detriment,
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respectively. We calculated B w and D w according to Wilson and Newhauser35 (see Chapter
4). We briefly review these factors here for the reader’s convenience.
B w and D w are based on corresponding basic principles, namely,
B

{ w =  `: w × 7: × : w × :

5.2

:q

and
D

} w =  ` w × 7 ×  w × 

5.3

q

where `: w is the probability of the  th endpoint, 7: is the relative strength or magnitude of the  th
endpoint, : w is a temporal factor that discounts radiation-related endpoints due to other nonradiation-related causes of mortality (i.e., competing causes of death), and : is a factor for other
considerations that might be important to the decision-making process (e.g., cost of treatment,
access to care, or patient preference). ` w, 7 ,  w, and  are the same for the detriment. B
in Eq. 5.2 is the number of benefits considered (in this case 1) and D in Eq. 5.3 is the number of
detriments considered (in this case 7). Table 5.1 lists the models and corresponding parameter
values used to study the cohort in this work. For simplicity, we assigned a value of unity to :
and  for all endpoints.
In order to assess the impact of uncertainties in the dose response on outcome optimizations, we
performed a sensitivity test by calculating ` w using six different dose-response models. The
most widely accepted of these models was the linear-non-threshold (LNT) model. We calculated
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` w for the risks of radiogenic cancer of the bladder, rectum, and remainder using LNT
following the BEIR VII methodology121. We calculated the risk of leukemia using the linearquadratic model recommended by the BEIR VII report121 following the methods of Taddei et
al.158 We next modified the LNT risk by applying two different linear-exponential relationships
and two different linear-plateau relationships29, 51, which is conceptually consistent with sublinear behavior at high (cytotoxic) exposures. Finally, we applied a mechanistic model for
radiogenic cancer induction following the methods of Dasu et al.115 Figure 5.1 plots
representative examples of these six risk models and demonstrates the range of dose-response
relationships considered in this study. Thus, we obtained a unique OORT treatment plan for each
combination of patient, modality, and risk model.

Figure 5.1. Representative examples of dose-response relationships. Excess absolute risk (EAR)
versus dose equivalent (H) for six different models for the risk of radiogenic cancer induction.
Models include linear-non-threshold121 (LNT), linear exponential51 with maxima at 10 Gy (LExp10) and at 40 Gy (L-Exp40), linear plateau51 with maxima at 10 Gy (L-Plat10) and at 40 Gy
(L-Plat40), and the mechanistic model of Dasu et al.115 (Mech.). Examples are for radiogenic
cancer of the bladder. Results for rectum, remainder, and leukemia are qualitatively similar.
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The second objective function, DORT , was based on dosimetric constraints and provided a
mode of comparison with current standards of care. We calculated DORT following the
methods of Wu and Mohan163 with,


¼

»*# »*#
DORT =   º +  (
º(
q

5.4

(q

»*#
where  is the weight for º , º is the dosimetric objective for the th target volume, (
is

the weight for º(»*# , and º(»*# is the dose-volume objective for the oth organ at risk (OAR). In
»*#
our case, the weights  and (
were numerically equivalent to our strength factors 7: and 7 ,

respectively (see Eqs. 5.2 and 5.3 and Table 5.1). We calculated º for a single target dose of 76
Gy. We calculated º(»*# for ten dose-volume constraints (see Table 5.2). Thus, we obtained one
DORT treatment plan for each patient and each treatment modality.
Table 5.2. Dose-volume constraints used for dose-optimized radiotherapy treatment planning.
Constraints were used for calculating the dose-volume objective, º(»*# , for the objective function
DORT (see Eq. 5.4) whereby the normal tissue should receive no greater than the dose specified
to the specified volume. Adapted from Rechner et al.29
Normal Tissue Dose (Gy
Relative
or Sv)
Volume (%)
Bladder
70
15
Rectum
40
60
”
45
50
”
60
40
”
70
15
”
75.6
10
”
78
5
Rectal Wall
60
70
”
79
30
Femoral Heads
45
50
5.2.4. Tests for Improved Projected Outcomes
We quantified the projected health outcome resulting from each optimized treatment plan (i.e.,
210 total treatment plans: 180 OORT and 30 DORT) by calculating the figure of merit () of
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Wilson and Newhauser35 (see Chapter 4). The  provides a framework for combining
arbitrary numbers and types of benefits and detriments from a planned radiation exposure,
accumulated over time, into a single metric. It is calculated for an individual radiotherapy patient
according to,
¸

 =  w ∆w

5.5

x

where the figure of merit at a point in time is,
w = { w × |1 − } w~

5.6

and where , ¹, { w and } w are as previously defined (see Eqs. 5.2 and 5.3). We calculated
the  for each of the 210 optimized treatment plans in consideration of the endpoints listed in
Table 5.1.
We used the ratio of ’s () to compare the projected long-term outcomes for
corresponding treatment plans (i.e., OORT and DORT) for each patient (: ), treatment modality
(o ), and risk model (o ). We calculated  according to,
|: , o , o ~ =

OORT |: , o , o ~
DORT |: , o ~

5.7

where OORT |: , o , o ~ and DORT |: , o ~ are the ’s calculated for OORT and
DORT treatment plans, respectively, for patient : , modality o , and risk model o . Thus,

|: , o , o ~ > 1 indicates that OORT has the superior projected longitudinal outcome
compared to DORT and |: , o , o ~ < 1 indicates that DORT has the superior
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projected longitudinal outcome compared to OORT. Figure 5.2 contains a flow chart depicting
the treatment-planning, optimization, and treatment-plan-evaluation methods described up to this
point.

Figure 5.2. Flow chart of the treatment-planning, optimization, and evaluation-and-comparison
methods. : refers to patient numbers 1 through 10, o refers to the three treatment modalities
(i.e., 6-MV photons, 15-MV photons, and protons), and o refers to the six dose-response
models used to project the risk of radiogenic-cancer incidence (see Figure 5.1).
We performed two statistical tests of significance in the differences between projected

longitudinal outcomes after OORT and DORT. Specifically, we tested for values of  that

were statistically significantly different than 1 in the sample of patients. First, we assessed

whether the majority of OORT treatment plans had projected longitudinal outcomes superior to
those of DORT treatment plans (i.e., inclusive of all patients, treatment modalities, and risk
models). To do this, we performed a one-sided sign test at the 95% significance level. The sign

 ) that does not require
test is a non-parametric test for the location of the sample median (
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any assumptions about the shape of the underlying distribution. Second, we assessed whether the
OORT treatment plan for each patient had a superior projected longitudinal outcome compared
to the DORT treatment plan for that patient. For this test, we rigorously propagated the 2-σ

uncertainties in  following the methods of Homann et al.164 for all patients and treatment
modalities using treatment plans optimized using the LNT late-risk model. We then used these

uncertainties to perform a one-sided z-test for each patient, : , and for each modality, o . Table

5.3 contains the details pertaining to each of these statistical tests.

Table 5.3. Statistical tests performed. Details include the name of the test, the null hypothesis
(· ), the alternate or test hypothesis (* ), and the significance level (l).
Test
·
*
l
 ∀¯: , o , o ° ≤ 1
 ∀¯: , o , o ° > 1 0.05
Sign Test




Z Test
0.05
|½ , o® , oLNT ~ ≤ 1
|
½ , o® , oLNT ~ > 1
 |o ~ = 
 |oyq ~∀¯o °
 differs
Friedman Test 1

0.05
≥ 1 
 differs
 o  = 
 oyq ∀0o 1
Friedman Test 2 
0.05
≥ 1 



Friedman Test 3
0.05
≥ 1  differs
:  = :yq ∀0: 1
Finally, we performed three sensitivity tests to determine whether the quantitative results were
influenced by a series of factors: treatment factors (e.g., the selection of treatment modality),
risk-projection factors (e.g., the late-risk model selection), and host factors (e.g., age, anatomical
variation such as target volume and organ-at-risk location). We achieved this by performing a
Friedman test for each influence factor. The Friedman test is a non-parametric test to determine
whether there is a significant difference between the medians of more than 2 populations. Table
5.3 lists the parameters relevant to performing these tests.
5.3. Results
Our optimizations of relative-fluence-weight combinations resulted in 180 OORT treatment
plans, 81 of which were unique fluence-weight combinations. These combinations tended to be
unique to the treatment-modality selection and patient (i.e., repeated combinations were largely
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for the same treatment modality and patient but multiple different late-risk models). 6-MV
Photon OORT plans consisted of the largest number of beams (i.e., 11 on average) while proton
OORT plans comprised the fewest number of beams (i.e., six on average). Our optimizations
resulted in 30 DORT treatment plans, all of which were unique combinations of fluence weights.
DORT treatment plans tended to comprise a greater number of beams than OORT (i.e., 12 for 6and 15-MV photon DORT and eight for proton DORT, on average). Only in one case were the
OORT and DORT treatment plans identical (i.e., patient number six, 6-MV photons, OORT
using all late-risk models except LNT). Figure 5.3 shows a representative example of the dose
distributions from each unique treatment plan for one patient and one treatment modality. These
data show that while the DORT plan distributed dose roughly evenly around the patient, OORT
treatment plans were characterized by heavily weighted lateral beams and other lower-weighted
beam angles.
5.3.1. Tests for Improved Projected Outcomes

Figure 5.4 shows a violin plot of the  (see Eq. 5.7) distribution, inclusive of all patients,
treatment modalities, and late-risk models. This plot reveals that the majority of the 

probability distribution resides in the region corresponding to a superior projected outcome from
OORT treatment plans compared to DORT treatment plans. Indeed, the sign test for the

magnitude of the median  compared to 1 resulted in a p-value < 0.05 and thus we rejected
the null hypothesis (see Table 5.3). This result suggests that the majority of OORT treatment

plans did lead to superior projected long-term health outcomes compared to their corresponding
DORT treatment plans.
Figure 5.5 shows the  for the subset of OORT treatment plans optimized using the LNT

late-risk model for each patient and each treatment modality. Error bars represent the 95%
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Figure 5.3. Representative example of unique treatment plans for one patient and one treatment
modality. Absorbed dose is pictured as a color wash overlaid onto the isocentric slice of the
patient computed tomography (CT) for (a) OORT based on late-risk calculated by the LNT
model, (b) OORT based on the L-Exp10 late-risk model, (c) OORT based on L-Exp40, L-Plat10,
and L-Plat40, and mechanistic late-risk models, and (d) DORT. Examples are shown for the 15MV photon treatment plans for patient number five and are representative.
confidence intervals in  values. This plot shows that all OORT treatment plans were

generally superior. More precisely, all OORT treatment plans except one (at 15 MV for patient
number three) had  magnitudes larger than one. Z-tests for all modalities and patients

except one resulted in a p-value < 0.05. These results suggest that the OORT methods led to
treatment plans with superior projected longitudinal health outcomes compared to DORT at the
95% confidence level for every patient and every treatment modality except for the 15-MV
photon treatment plan for patient number three (p = 0.1). It is important to note that the low

 for patient number three was a result of an unusually high value of DORT rather than
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Figure 5.4. Violin plot of the  for all patients, treatment modalities, and risk-model
selections. Plot of the ratio of OORT and DORT ’s (, see Eq. 5.7) versus the kernel
density (KD) where KD describes the likelihood of a given  magnitude. The white box
 ). The horizontal dashed line represents an 
indicates the median  (
magnitude of 1 where all points above this line indicate that OORT plans had a superior
projected outcome compared to DORT plans and points below this line indicate that DORT plans
had a superior projected outcome compared to OORT plans.
a particularly low value of OORT . The most-likely explanation for this is that patient number

three had a larger separation between his PTV and all of his OARs than average in the

population, thus simplifying the optimization problem and enabling both DORT and OORT to
find favorable fluence-weight combinations.
Figure 5.6 shows violin plots of the  distributions for treatment plans grouped by
treatment modality, late-risk model, and patient. These plots reveal that the majority of all
probability distributions are > 1. This suggests that, qualitatively, the superior projected outcome
of OORT treatment plans was generalizable across all influence factors (i.e., treatment modality,
late-risk model, and host characteristics). This figure also reveals, however, that there was

 for distributions grouped by treatment modality and patient, but not for
variation in the 
those grouped by late-risk model. The Friedman tests resulted in p-values < 0.05 for plots a and c
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Figure 5.5. Scatter plot of results for treatment plans based on the LNT late-risk model. Ratio of
OORT to DORT ’s (, see Eq. 5.7) versus patient number (: ). Error bars represent
the 95% confidence intervals in the  values based on standard error-propagation methods.
The solid horizontal line represents an  magnitude of 1 where points above this line
indicate that OORT treatment plans had superior projected outcomes compared to DORT
treatment plans and points below this line indicate that DORT plans had projected outcomes
superior to those of OORT treatment plans.
 ’s were equivalent (see Table 5.3). This
and thus we rejected the null hypothesis that all 

indicates that the quantitative results were influenced, as expected, by the selection of treatment
 grouped by late-risk model
modality and by host factors. The Friedman test for the 

indicated that we could not reject the null hypothesis (p ≫ 0.05), suggesting that the selection of

late-risk model did not influence the optimization results.
5.4. Discussion
In this study, we developed a generally applicable method to directly optimize projected
longitudinal health outcomes. We demonstrated this new method by optimizing the relative
fluence weight of photon and proton radiotherapy beams in a sample of prostate-cancer patients
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in an entirely new and different way, i.e., to improve the projected longitudinal health outcome
rather than to meet physical constraints on the dose distribution in the patient. The major finding
of this work is that it does appear feasible to directly optimize radiotherapy treatment plans based
on the longitudinal (i.e., long- and short-term) health outcomes associated with the therapeutic
and stray radiation exposures in individual patients. The specific results of this study suggest that
doing so is superior to optimizations aiming to meet dose-volume constraints as evidenced by the
rejection of the null hypothesis in both population-based and individual statistical tests.
This study provides a simple and complete framework for optimizing radiotherapy treatment
plans directly on the basis of the clinical goals in consideration of all outcomes (i.e., beneficial
and detrimental, long- and short-term, fatal and non-fatal) associated with the total dose (i.e.,
therapeutic and stray) deposited in all of the tissues (i.e., diseased and healthy) in individual
patients, the implications of which could be broad. This framework has the potential to increase
personalization in radiotherapy treatment planning, whereby dosimetric-constraint driven
optimizations are superseded by the direct optimization of projected patient-specific health
outcomes. The discrete nature of scalar dosimetric constraints comprise a form of incomplete
information (on the dose response) for the optimization algorithm. The missing information
precludes the optimization algorithms from finding the best plan. Furthermore, the dosimetric
constraints are not necessarily representative of the patient outcome19. In this study, the best
projected health outcomes were obtained by optimizing the projected health outcome directly.
Specifically, we were able to decrease the cumulative risk of long- and short-term detrimental
endpoints by an average of 3% and increase the tumor control probability by an average of 1%
compared to conventional dose-optimization methods. We estimate that this corresponds to
adding up to 7 additional healthy months to the patient’s lifetime compared to that expected from
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Figure 5.6. Violin plots of three influence factors. Plots of the ratio of OORT and DORT ’s
(, see Eq. 5.7) grouped by (a) treatment modality, (b) late-risk model, and (c) patient
number versus the kernel density (KD). KD represents the likelihood of a given 
 ) and the horizontal dashed lines
magnitude. The white boxes indicate the median  (
separate  magnitudes indicating that OORT treatment plans had projected longitudinal
outcomes superior to those of DORT treatment plans (i.e., those > 1) from  magnitudes
indicating that DORT treatment plans had projected outcomes superior to OORT treatment plans
(i.e., those < 1). The inlay in panel (c) shows the probability distribution for patient number three
in greater detail.
dose-optimized treatment plans. The results of this study also indicated that the methods were
generalizable across three treatment modalities, six models for late risk, and ten unique
combinations of host factors (e.g., age, tumor size, organ-at-risk location and size). Although, the
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degree of improvement varied with the selection of treatment modality and the unique
combination of patient-specific parameters.
The results of this study are in agreement with previous studies in the literature. In the most
directly comparable study, Modiri et al.31 optimized the relative fluence weight for photontherapy treatments of one breast and one Hodgkin lymphoma case by minimizing the total risk of
tumor recurrence and mortality from radiation-related late effects. Their outcome optimizations
resulted in a total decrease in risk of detrimental effects of less than 2% for the breast case and
6% for the Hodgkin lymphoma case. Our average decrease in cumulative risk of 3% is in
agreement with their results. In another related study, Rechner et al.29 optimized beam angle and
relative fluence weight for one prostate-cancer patient receiving proton therapy by minimizing
the risk of second cancer in the rectum and bladder. They were able to reduce the excess relative
risk of second cancer in the rectum and bladder by 30% and 21%, respectively. This is similar to
the results of our longitudinally optimized outcomes, which reduced the excess relative risk of
second cancer in the rectum and bladder by an average of 23% and 21%, respectively.
This study has several notable strengths. First, we minimized methodological bias by utilizing a
recently developed research TPS capable of calculating the total absorbed dose from both
therapeutic and stray radiation exposures, the latter of which is usually neglected. This enabled
us to optimize complete projections of the long- and short-term effects in each individual patient.
Additionally, we used a new framework for combining arbitrary numbers and types of beneficial
and detrimental health effects of planned radiation exposures to assess the projected outcomes
resulting from OORT and DORT treatment plans. This study also explored a wide array of
influence factors including charged and uncharged particles, six different late-risk models, and
ten patients, each with their own unique combination of host factors like age and anatomical
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characteristics, such as target volume and organ-at-risk location. This enabled us to explore the
generalizability of our OORT methods across three influence factors. Finally, the exhaustivesearch methods employed in this study had two important strengths. First, they reliably found the
global minimum in each and every optimization. Gradient-search iterative optimization
techniques common in contemporary radiotherapy optimization are known to be limited by the
“local minima” problem whereby they are susceptible to getting trapped in a local minimum and
missing the true optimal result, the global minimum162. Our exhaustive search, however, avoided
this limitation. Second, the exhaustive search provided additional information on the parameter
space of the optimization. Different iterative optimization techniques are best suited to specific
parameter-space characteristics. Prior to this study, the parameter-space characteristics for the
new outcome-based objective function were unknown and thus it was not clear which iterative
optimization algorithm was best suited to outcome optimizations. Thus, the additional
information yielded by the exhaustive search could guide the selection of appropriate
optimization algorithms in the future.
This study also had several limitations. First, the outcome-optimization methods presented here
rely heavily on the availability of dose-response functions for all tissues and endpoints to be
considered, the knowledge of which is still incomplete. The functional form of dose-response
functions, however, is well understood for many endpoints and most commonly taken to be
sigmoidal or linear, depending on the endpoint. Thus we believe it would be possible to translate
the information contained in currently used, discrete, scalar dose objectives into continuous doseresponse functions matching a known or assumed functional form (e.g., linear, sigmoidal, linear
exponential, linear plateau, etc.) for preliminary inclusion in our framework. These models could
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easily be modified and updated as radiobiological and epidemiological understanding of the true
relationships are refined in the future.
Another limitation is that, due to the conceptually different approach taken here, relatively less is
known about how the uncertainty in the dose-response functions (e.g., due to interpatient
variations) affects the certainty of the optimization result. This issue may be addressed, however,
by performing additional sensitivity tests, such as those performed in this work and by others29,
31, 51

, to assess the sensitivity of the optimization to uncertainties in the dose-response functions.

Another limitation related to the conceptually different approach is the question of continuity of
care. This is not a serious limitation, however, because it is possible to do both outcome- and
dose-based optimizations separately (allowing for training and retrospective evaluations of
projected versus actual outcomes) or to combine OORT with DORT to create a hybrid
objective function, H , as in

H = OORT × DORT .

5.8

Our preliminary tests revealed that H collapses to the hitherto method (i.e., dosimetric

optimization using DORT alone) thus providing a mechanism to do comparative studies and
ensure continuity of care.
Finally, the optimization technique that we utilized (i.e., the exhaustive search) was not
representative of standard-of-care methods in most clinical settings (i.e., iterative gradient-search

optimization techniques). Our preliminary studies suggest, however, that OORT should work to
replace DORT to guide an iterative optimization algorithm. In fact, OORT decreased the

number of local minima in the parameter space by nearly 4% compared to DORT . This suggests

that OORT appears to be less susceptible to the local minima problem than standard-of-care
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methods. Additionally, OORT increased the slope of the gradient (assessed over the 1000 top-

ranked values) by 44% compared to DORT . These findings suggest that OORT is compatible
with clinical optimization algorithms and could computationally simplify the optimization
problem.
5.5. Conclusion
The results of this study provide promising evidence that it may be possible to improve the
projected longitudinal health outcomes of radiotherapy patients by directly optimizing the
projected health outcomes themselves (i.e., by replacing discrete, dose-based objectives and
penalties with continuous, long- and short-term dose-response functions). The methods
developed in this work are generalizable and may consider arbitrary numbers and types of

endpoints. Thus, they enable all important aspects of cancer survivorship to be taken into account
and provide a more direct approach to realizing the full beneficial potential of cancer
radiotherapy.
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Chapter 6. Discussion and Conclusions
This work, for the first time, tested the end-to-end feasibility of directly optimizing outcomes
considering beneficial and detrimental, long- and short-term, and fatal and non-fatal effects
associated with all of the radiation exposures in all of the tissues of individuals, groups, and
populations. This necessitated the development and testing of several tools to calculate the dose
from both therapeutic and stray exposures in individuals, evaluate the dose across the wide
dynamic range of magnitudes, combine the risks of varying types and severity, and directly
optimize the outcomes. The major finding is that it is feasible to directly optimize the biological
goal, the projected health outcome, of planned radiation exposures (e.g., industrial, diagnostic, or
therapeutic) in a personalized manner. Furthermore, these methods do not necessitate a complete
abandonment of current guidelines and limits, thus providing backwards compatibility with
current standards of practice.
6.1. Implications
The specific results of this study suggest that there is an opportunity to improve health outcomes
by algorithmically and directly optimizing the outcomes themselves, rather than indirectly
optimizing dose distributions via scalar dosimetric constraints that are poor surrogates for the
health outcome19. With the new methods developed here, it is now possible to consider all of the
benefits and detriments for which there exists any information on the dose response. For
example, in the field of radiotherapy, recent research in the fields of medical physics, radiation
biology, and epidemiology have rapidly expanded the knowledge of the potential beneficial and
detrimental health effects and their relationships with dose121, 150. This deluge of information now
necessitates a framework to algorithmically consider arbitrary numbers of opposing forces in a
personalized manner. Thus, we find ourselves at an auspicious time when a framework that is
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capable of utilizing all of the available information could bring the realization of the full
beneficial potential of radiotherapy within reach. The tools developed in this work could be
implemented, for example, to enhance radiotherapy treatment-planning methods (Chapter 5).
These new methods, however, are not limited to radiotherapy. They could also be applied to
other medical and non-medical applications as computer-aided decision tools (Chapter 4).
6.2. Coherence with Existing Literature
Due to the fact that previous works in this area took relatively fewer of the potential health
effects into account, it is difficult to draw direct quantitative comparisons. Rechner et al.29
optimized proton radiotherapy treatment plans for a prostate radiotherapy patient by minimizing
the cumulative risk of second cancer in the rectum and bladder. Our results are in agreement with
those of Rechner et al. in that both studies revealed an opportunity to reduce the cumulative risk
to the patient while maintaining or improving the projected benefits by directly optimizing the
continuous dose-response functions. Furthermore, Rechner explored the influence of risk-model
selection on the optimization result by repeating their optimizations for six different late-risk
models. They found that this resulted in three unique treatment plans for one patient, depending
on the selection of risk model. We also explored the effects of six late-risk models on our
optimization results and found that on average, these risk models resulted in three unique plans
for each patient. Qualitatively, our results are in agreement with those of Homann et al.164 who
showed the importance of a personalized approach to radiotherapy treatment planning in a
population of female Hodgkin-lymphoma patients. In our study of male prostate-cancer patients,
the largest quantitative variations were due to inter-patient variation in host factors, such as age
and anatomical characteristics (e.g., tumor volume, organ-at-risk volume and location). This
points towards a theoretical advantage to optimizing treatment plans in a personalized manner
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for each and every patient. Our findings for prostate radiotherapy differ from those of prior
studies of pediatric medulloblastoma patients receiving craniospinal irradiation, which showed a
class solution (i.e., little or no need for personalized optimization)15, 165. In the most directly
comparable study, Modiri et al.31 optimized the beam angle and relative fluence weight for two
patients by minimizing the cumulative risk of early and late health effects. Although they
neglected the stray radiation exposures, Modiri et al. found that such methods could reduce the
cumulative risk by between 1% and 6%. This quantitatively agrees with our results, which
reduced the cumulative risk of early and late effects by an average of 3%.
6.3. Strengths of the Study
This study had several notable strengths. First, we specifically designed our framework to be
generalizable; scalable to arbitrary health effects, tissues, and organs; and broadly applicable. In
fact, we demonstrated these methods in the field of cancer radiotherapy, diagnostic imaging, and
emergency response. The comprehensive and algorithmic approach developed in this work was
also a strength in that it decreased subjectivity and concomitant requirements for user skill.
Furthermore, the exhaustive-search optimization methods implemented here also decreased
requirements for user skill as no initial guess was required or made. Thus, the methods were not
susceptible to erroneous results due to a poor choice of initial guess. Another major strength is
that the tools developed here are conceptually transparent (i.e., simple and intuitive). This is
especially important for clinicians and others who are responsible for ensuring that any decisions
are ethical and therefore in keeping with an individual’s wishes (i.e., autonomy) and well-being
(i.e., beneficence). Finally, we performed an analysis of uncertainty, thus ensuring the
comprehensive consideration of the significance of our findings and proper interpretation of the
results.
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6.4. Limitations of the Study
This study was not free from features that might be viewed as limitations. First, we only tested
the practical application of our new methods to one cancer treatment site, the prostate. This was
not a significant limitation because with this one site, we explored 3 different treatment
modalities, 10 patients, and 1.3 million treatment plans. Thus, while future studies are needed to
confirm the findings at different treatment sites, our findings illustrate the capabilities and
potential of this approach. Additionally, we only simulated conventional radiotherapy and did
not explore the applicability to more advanced treatment deliveries, such as intensity modulated
radiotherapy (IMRT) or volumetric arc therapy (VMAT), for which exhaustive-search methods
may not be feasible. Treatment planning for these delivery techniques typically involves
gradient-search iterative optimization methods. This was not considered a serious limitation,
however, because our framework should work with gradient-search optimization algorithms. In
fact, when compared to the objective function commonly used to guide these algorithms, our
outcome-based objective function decreased the number of local minima and increased the
gradient near the global minimum. This suggests that our new figure of merit could
computationally simplify the iterative optimization problem. Finally, the entirety of this study
was performed in silico rather than in vivo. This, however, is common and indeed necessary. The
long follow-up times that would be required to observe late effects, which have latencies on the
order or years or decades, combined with rapidly evolving technology would render the results
of an in vivo study obsolete by the time adequate follow-up data were acquired.
6.5. Conclusion
This work demonstrated that it is, in fact, possible to combine all of the potential effects (i.e.,
beneficial and detrimental, long-term and short-term, fatal and non-fatal) of a medical
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intervention, thereby enabling the improvement of longitudinal health outcome as opposed to the
treatment benefits alone. Our example in cancer radiotherapy revealed the opportunity to
improve the probability of treatment benefit by an average of 1%, while simultaneously
decreasing the cumulative probability of long- and short-term treatment side effects by an
average of 3% compared to contemporary treatment-planning techniques. An algorithmic
approach such as that developed in this work will become necessary to improve outcomes for
many patients with serious illnesses and who face treatment side effects. In conclusion, this
work, taken together, provides an objective and comprehensive methodological framework that
could enable a paradigm shift towards more objective and automated approaches to improving
patient outcomes.
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Appendix B. Additional Generalized Gamma Index Equations
The generalized gamma index can be calculated for 2- and 3-dimensional analyses by the
following equations:
2-Dimensional Analysis:
ΓG m , Zm , c , Zc 
=


⎧   m , Zm , c , Zc  "# m , Zm , c , Zc 

+
, for m , Zm at therapeutic locations
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3-Dimensional Analysis:
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B.6

B.7

B.8
B.9

2G m , Zm , Àm  = min0ΓG m , Zm , Àm , c , Zc , Àc 1∀0c , Zc , Àc 1
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